QUARTERLY REPORT

Q3 FY2025 — Quarterly report (Form 10-Q)

Q3 FY2025PDF · 48 pages569 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark one)
x True QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2025
OR
o False TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from 	to
THE PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio 	OH 	1-434 	31-0411980
(State of Incorporation) 	(Commission File Number) 	(I.R.S. Employer Identification Number)
One Procter & Gamble Plaza 	Cincinnati 	OH
One Procter & Gamble Plaza, Cincinnati, Ohio 	45202
(Address of principal executive offices) 	(Zip Code)
(513) 983-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol 	Name of each exchange on which registered
Common Stock, without Par Value 	PG 	NYSE
1.375% Notes due 2025 	PG25 	NYSE
0.110% Notes due 2026 	PG26D 	NYSE
3.250% EUR Notes due 2026 	PG26F 	NYSE
4.875% EUR Notes due May 2027 	PG27A 	NYSE
1.200% Notes due 2028 	PG28 	NYSE
3.150% EUR Notes due 2028 	PG28B 	NYSE
1.250% Notes due 2029 	PG29B 	NYSE
1.800% Notes due 2029 	PG29A 	NYSE
6.250% GBP Notes due January 2030 	PG30 	NYSE
0.350% Notes due 2030 	PG30C 	NYSE
0.230% Notes due 2031 	PG31A 	NYSE
3.250% EUR Notes due 2031 	PG31B 	NYSE
5.250% GBP Notes due January 2033 	PG33 	NYSE
3.200% EUR Notes due 2034 	PG34C 	NYSE
1.875% Notes due 2038 	PG38 	NYSE
0.900% Notes due 2041 	PG41 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of
"large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	þ 	Accelerated filer 	¨
Non-accelerated filer 	¨ 	Smaller reporting company 	¨ 	False
Emerging growth company 	¨ 	False
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False
There were 2,344,542,034 shares of Common Stock outstanding as of March 31, 2025.

-- 1 of 48 --

FORM 10-Q TABLE OF CONTENTS 	Page
PART I 	Item 1. 	Financial Statements 	1
Consolidated Statements of Earnings 	1
Consolidated Statements of Comprehensive Income 	1
Consolidated Balance Sheets 	2
Consolidated Statements of Shareholders' Equity 	3
Consolidated Statements of Cash Flows 	5
Notes to Consolidated Financial Statements 	6
Note 1: Basis of Presentation 	6
Note 2: New Accounting Pronouncements and Policies 	6
Note 3: Segment Information 	6
Note 4: Goodwill and Intangible Assets 	7
Note 5: Earnings Per Share 	9
Note 6: Share-Based Compensation and Postretirement Benefits 	9
Note 7: Risk Management Activities and Fair Value Measurements 	10
Note 8: Accumulated Other Comprehensive Income/(Loss) 	11
Note 9: Commitments and Contingencies 	11
Note 10: Supplier Finance Programs 	12
Note 11: Restructuring Program 	12
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations 	13
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	28
Item 4. 	Controls and Procedures 	28
PART II 	Item 1. 	Legal Proceedings 	28
Item 1A. 	Risk Factors 	28
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 	28
Item 5. 	Other Information 	29
Item 6. 	Exhibits 	30
Signature 	30

-- 2 of 48 --

The Procter & Gamble Company 1
PART I. FINANCIAL INFORMATION
Item 1. 	Financial Statements
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
Three Months Ended March 31 	Nine Months Ended March 31
Amounts in millions except per share amounts 	2025 	2024 	2025 	2024
NET SALES 	$ 	19,776 $ 	20,195 $ 	63,395 $ 	63,507
Cost of products sold 	9,694 	9,855 	30,533 	30,500
Selling, general and administrative expense 	5,524 	5,880 	16,765 	17,006
Indefinite-lived intangible asset impairment charge 	— 	— 	— 	1,341
OPERATING INCOME 	4,558 	4,460 	16,096 	14,660
Interest expense 	(217) 	(233) 	(695) 	(705)
Interest income 	111 	104 	365 	366
Other non-operating income/(expense), net 	210 	260 	(120) 	570
EARNINGS BEFORE INCOME TAXES 	4,661 	4,592 	15,646 	14,891
Income taxes 	868 	812 	3,207 	3,061
NET EARNINGS 	3,793 	3,781 	12,439 	11,830
Less: Net earnings attributable to noncontrolling interests 	23 	27 	80 	88
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	3,769 $ 	3,754 $ 	12,359 $ 	11,742
NET EARNINGS PER COMMON SHARE
Basic 	$ 	1.58 $ 	1.56 $ 	5.16 $ 	4.89
Diluted 	$ 	1.54 $ 	1.52 $ 	5.03 $ 	4.75
Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended March 31 	Nine Months Ended March 31
Amounts in millions 	2025 	2024 	2025 	2024
NET EARNINGS 	$ 	3,793 $ 	3,781 $ 	12,439 $ 	11,830
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation 	367 	(211) 	623 	(128)
Unrealized gains/(losses) on investment securities 	2 	— 	3 	(2)
Unrealized gains/(losses) on defined benefit postretirement plans 	(39) 	7 	(37) 	(23)
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX 	330 	(204) 	590 	(153)
TOTAL COMPREHENSIVE INCOME 	4,123 	3,577 	13,029 	11,677
Less: Comprehensive income attributable to noncontrolling interests 	24 	26 	78 	85
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	4,099 $ 	3,551 $ 	12,951 $ 	11,592
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.

-- 3 of 48 --

2 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Amounts in millions 	March 31, 2025 	June 30, 2024
Assets
CURRENT ASSETS
Cash and cash equivalents 	$ 	9,116 $ 	9,482
Accounts receivable 	6,139 	6,118
INVENTORIES
Materials and supplies 	1,935 	1,617
Work in process 	957 	929
Finished goods 	4,508 	4,470
Total inventories 	7,400 	7,016
Prepaid expenses and other current assets 	1,780 	2,095
TOTAL CURRENT ASSETS 	24,435 	24,709
PROPERTY, PLANT AND EQUIPMENT, NET 	22,728 	22,152
GOODWILL 	40,476 	40,303
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 	21,836 	22,047
OTHER NONCURRENT ASSETS 	13,508 	13,158
TOTAL ASSETS 	$ 	122,984 $ 	122,370
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable 	$ 	14,512 $ 	15,364
Accrued and other liabilities 	9,847 	11,073
Debt due within one year 	9,889 	7,191
TOTAL CURRENT LIABILITIES 	34,248 	33,627
LONG-TERM DEBT 	24,252 	25,269
DEFERRED INCOME TAXES 	6,481 	6,516
OTHER NONCURRENT LIABILITIES 	5,458 	6,398
TOTAL LIABILITIES 	70,439 	71,811
SHAREHOLDERS’ EQUITY
Preferred stock 	781 	798
Common stock – shares issued – 	March 2025 	4,009.2
June 2024 	4,009.2 	4,009 	4,009
Additional paid-in capital 	68,615 	67,684
Reserve for ESOP debt retirement 	(672) 	(737)
Accumulated other comprehensive loss 	(11,307) 	(11,900)
Treasury stock 	(138,073) 	(133,379)
Retained earnings 	128,919 	123,811
Noncontrolling interest 	273 	272
TOTAL SHAREHOLDERS’ EQUITY 	52,545 	50,559
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 	$ 	122,984 $ 	122,370
See accompanying Notes to Consolidated Financial Statements.

-- 4 of 48 --

The Procter & Gamble Company 3
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Three Months Ended March 31, 2025
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock Retained
Earnings Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE DECEMBER 31,
2024 	2,344,852 $4,009 	$788 	$68,283 	($707) 	($11,637) ($137,112) 	$127,544 	$275 	$51,443
Net earnings 	3,769 	23 	3,793
Other comprehensive
income/(loss) 	330 	1 	330
Dividends and dividend
equivalents
($1.0065 per share):
Common 	(2,367) 	(2,367)
Preferred 	(71) 	(71)
Treasury stock purchases 	(7,966) 	(1,351) 	(1,351)
Employee stock plans 	6,836 	331 	384 	715
Preferred stock conversions 	820 	(7) 	1 	6 	—
ESOP debt impacts 	35 	44 	79
Noncontrolling interest, net 	— 	(26) 	(26)
BALANCE MARCH 31, 2025 	2,344,542 $4,009 	$781 	$68,615 	($672) 	($11,307) ($138,073) 	$128,919 	$273 	$52,545
Nine Months Ended March 31, 2025
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2024 	2,357,051 $4,009 	$798 	$67,684 	($737) 	($11,900) ($133,379) 	$123,811 	$272 	$50,559
Net earnings 	12,359 	80 	12,439
Other comprehensive
income/(loss) 	592 	(2) 	590
Dividends and dividend
equivalents
($3.0195 per share):
Common 	(7,121) 	(7,121)
Preferred 	(215) 	(215)
Treasury stock purchases 	(34,235) 	(5,813) 	(5,813)
Employee stock plans 	19,662 	929 	1,104 	2,033
Preferred stock conversions 	2,063 	(17) 	2 	15 	—
ESOP debt impacts 	64 	86 	150
Noncontrolling interest, net 	— 	(77) 	(77)
BALANCE MARCH 31, 2025 	2,344,542 $4,009 	$781 	$68,615 	($672) 	($11,307) ($138,073) 	$128,919 	$273 	$52,545
See accompanying Notes to Consolidated Financial Statements.

-- 5 of 48 --

4 The Procter & Gamble Company
Three Months Ended March 31, 2024
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE DECEMBER 31,
2023 	2,353,021 $4,009 	$809 	$66,935 	($782) 	($12,167) ($131,887) 	$121,617 	$294 	$48,829
Net earnings 	3,754 	27 	3,781
Other comprehensive
income/(loss) 	(203) 	(1) 	(204)
Dividends and dividend
equivalents
($0.9407 per share):
Common 	(2,221) 	(2,221)
Preferred 	(69) 	(69)
Treasury stock purchases 	(6,046) 	(977) 	(977)
Employee stock plans 	12,201 	459 	685 	1,144
Preferred stock conversions 	959 	(8) 	1 	7 	—
ESOP debt impacts 	45 	51 	97
Noncontrolling interest, net 	— 	(46) 	(46)
BALANCE MARCH 31, 2024 	2,360,135 $4,009 	$801 	$67,395 	($737) 	($12,370) ($132,172) 	$123,132 	$275 	$50,333
Nine Months Ended March 31, 2024
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock Retained
Earnings Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2023 	2,362,120 $4,009 	$819 	$66,556 	($821) 	($12,220) ($129,736) 	$118,170 	$288 	$47,065
Net earnings 	11,742 	88 	11,830
Other comprehensive
income/(loss) 	(150) 	(3) 	(153)
Dividends and dividend
equivalents
($2.8221 per share):
Common 	(6,671) 	(6,671)
Preferred 	(209) 	(209)
Treasury stock purchases 	(22,768) 	(3,493) 	(3,493)
Employee stock plans 	18,552 	836 	1,041 	1,878
Preferred stock conversions 	2,232 	(18) 	3 	15 	—
ESOP debt impacts 	85 	99 	184
Noncontrolling interest, net 	— 	(98) 	(98)
BALANCE MARCH 31, 2024 	2,360,135 $4,009 	$801 	$67,395 	($737) 	($12,370) ($132,172) 	$123,132 	$275 	$50,333
See accompanying Notes to Consolidated Financial Statements.

-- 6 of 48 --

The Procter & Gamble Company 5
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended March 31
Amounts in millions 	2025 	2024
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD 	$ 	9,482 $ 	8,246
OPERATING ACTIVITIES
Net earnings 	12,439 	11,830
Depreciation and amortization 	2,124 	2,135
Share-based compensation expense 	364 	433
Deferred income taxes 	183 	(206)
Loss/(gain) on sale of assets 	782 	(51)
Indefinite-lived intangible asset impairment charge 	— 	1,341
Change in accounts receivable 	(79) 	(692)
Change in inventories 	(409) 	(47)
Change in accounts payable and accrued and other liabilities 	(1,666) 	56
Change in other operating assets and liabilities 	(1,125) 	(1,196)
Other 	218 	490
TOTAL OPERATING ACTIVITIES 	12,832 	14,092
INVESTING ACTIVITIES
Capital expenditures 	(2,777) 	(2,539)
Proceeds from asset sales 	64 	77
Acquisitions, net of cash acquired 	(11) 	(21)
Other investing activity 	(33) 	(503)
TOTAL INVESTING ACTIVITIES 	(2,755) 	(2,986)
FINANCING ACTIVITIES
Dividends to shareholders 	(7,319) 	(6,863)
Additions to short-term debt with original maturities of more than three months 	5,905 	2,961
Reductions in short-term debt with original maturities of more than three months 	(3,781) 	(7,523)
Net additions/(reductions) to other short-term debt 	(543) 	2,331
Additions to long-term debt 	995 	1,598
Reductions in long-term debt 	(1,478) 	(2,335)
Treasury stock purchases 	(5,800) 	(3,490)
Impact of stock options and other 	1,601 	965
TOTAL FINANCING ACTIVITIES 	(10,420) 	(12,356)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	(22) 	(168)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	(365) 	(1,418)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD 	$ 	9,116 $ 	6,828
See accompanying Notes to Consolidated Financial Statements.

-- 7 of 48 --

6 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries ("the Company," "Procter & Gamble,"
"P&G," "we" or "our") should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024. We have
prepared these statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations
of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Note that certain columns and rows may not add due to rounding. In
the opinion of management, the accompanying Consolidated Financial Statements contain all normal recurring adjustments necessary to present fairly the
financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements
may not necessarily be indicative of annual results.
2. New Accounting Pronouncements and Policies
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, “Segment Reporting:
Improvements to Reportable Segment Disclosures”. This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending June 30, 2025 and our interim periods within the fiscal year ending June 30, 2026. The guidance will require
additional disclosures in the Segment Information footnote, but will not have a material impact on our Consolidated Financial Statements.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes: Improvements to Income Tax Disclosures”. This guidance requires consistent
categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective
for our fiscal year ending June 30, 2026. We are currently assessing the impact of this guidance on our disclosures.
In November 2024, the FASB issued ASU No. 2024-03, “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures:
Disaggregation of Income Statement Expenses”. This guidance requires disclosures about significant expense categories, including but not limited to, inventory
purchases, employee compensation, depreciation, amortization and selling expenses. This amendment is effective for our fiscal year ending June 30, 2028 and
our interim periods within the fiscal year ending June 30, 2029. We are currently assessing the impact of this guidance on our disclosures.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial
Statements.
3. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and
5) Baby, Feminine & Family Care. Our five reportable segments are comprised of:
• Beauty: Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Personal Care (Antiperspirants and Deodorants, Personal Cleansing); Skin Care
(Facial Moisturizers, Cleaners and Treatments);
• Grooming: Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming);
• Health Care: Oral Care (Toothbrushes, Toothpastes, Other Oral Care); Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional,
Surface Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Menstrual Care); Family Care
(Paper Towels, Tissues, Toilet Paper).
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 8 of 48 --

The Procter & Gamble Company 7
Operating segments as a percentage of consolidated net sales are as follows:
% of Net sales by operating segment
Three Months Ended March 31 	Nine Months Ended March 31
2025 	2024 	2025 	2024
Fabric Care 	23 % 	23 % 	23 % 	23 %
Home Care 	12 % 	13 % 	12 % 	12 %
Baby Care 	9 % 	9 % 	9 % 	9 %
Family Care 	9 % 	9 % 	9 % 	9 %
Hair Care 	9 % 	9 % 	9 % 	9 %
Grooming 	8 % 	8 % 	8 % 	8 %
Oral Care 	8 % 	8 % 	8 % 	8 %
Personal Health Care 	7 % 	6 % 	7 % 	7 %
Feminine Care 	6 % 	6 % 	6 % 	6 %
Personal Care 	6 % 	5 % 	6 % 	5 %
Skin Care 	3 % 	4 % 	3 % 	4 %
Total 	100 % 	100 % 	100 % 	100 %
% of Net sales by operating segment excludes sales recorded in Corporate.
Effective July 1, 2024, the Beauty reportable business segment separated Skin and Personal Care into individual operating segments, Skin Care and Personal Care. This
transition included separation of the management team, strategic decision-making, innovation plans, financial targets, budgets and management reporting.
The following is a summary of reportable segment results:
Three Months Ended March 31 	Nine Months Ended March 31
Net Sales
Earnings/(Loss)
Before Income
Taxes
Net
Earnings/(Loss) 	Net Sales
Earnings/(Loss)
Before Income
Taxes
Net
Earnings/(Loss)
Beauty 	2025 $ 	3,490 $ 	684 $ 	539 $ 	11,231 $ 	2,746 $ 	2,158
2024 	3,550 	753 	587 	11,496 	3,114 	2,426
Grooming 	2025 	1,505 	404 	321 	4,980 	1,493 	1,206
2024 	1,539 	379 	303 	4,997 	1,450 	1,165
Health Care 	2025 	2,880 	734 	569 	9,277 	2,662 	2,068
2024 	2,873 	687 	525 	9,119 	2,508 	1,933
Fabric & Home Care 	2025 	6,948 	1,642 	1,285 	22,233 	5,709 	4,473
2024 	7,169 	1,692 	1,301 	22,230 	5,741 	4,446
Baby, Feminine & Family Care 	2025 	4,755 	1,150 	880 	15,155 	3,997 	3,065
2024 	4,936 	1,299 	997 	15,268 	4,144 	3,174
Corporate 	2025 	198 	48 	200 	520 	(961) 	(531)
2024 	128 	(218) 	68 	398 	(2,066) 	(1,314)
Total Company 	2025 $ 	19,776 $ 	4,661 $ 	3,793 $ 	63,395 $ 	15,646 $ 	12,439
2024 	20,195 	4,592 	3,781 	63,507 	14,891 	11,830
4. Goodwill and Intangible Assets
Goodwill is allocated by reportable segment as follows:
Beauty 	Grooming 	Health Care Fabric & Home
Care Baby, Feminine &
Family Care 	Total Company
Goodwill at June 30, 2024 	$ 	13,723 $ 	12,633 $ 	7,638 $ 	1,810 $ 	4,499 $ 	40,303
Acquisitions and divestitures 	— 	— 	— 	— 	— 	—
Translation and other 	73 	47 	32 	5 	17 	173
Goodwill at March 31, 2025 	$ 	13,796 $ 	12,679 $ 	7,670 $ 	1,816 $ 	4,516 $ 	40,476
Goodwill increased from June 30, 2024, primarily due to currency translation.
(1)
(2)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 9 of 48 --

8 The Procter & Gamble Company
Identifiable intangible assets at March 31, 2025, were comprised of:
Gross Carrying Amount 	Accumulated Amortization
Intangible assets with determinable lives 	$ 	9,047 	$ 	(6,816)
Intangible assets with indefinite lives 	19,605 	—
Total identifiable intangible assets 	$ 	28,652 	$ 	(6,816)
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives primarily
consist of brands. The amortization expense of determinable-lived intangible assets for the three months ended March 31, 2025 and 2024, was $78 and $83,
respectively. For the nine months ended March 31, 2025 and 2024, amortization expense was $241 and $255, respectively.
Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair
value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach,
which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. If the resulting fair value is
less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets
occurs during the three months ended December 31. Other than our Gillette indefinite-lived intangible asset, our goodwill reporting units and indefinite-lived
intangible assets have fair values that significantly exceed their underlying carrying values.
As previously disclosed, the carrying value of the Gillette indefinite-lived intangible asset was impaired during the fiscal year ended June 30, 2024. The
impairment charge arose due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of a new restructuring
program focused primarily in certain Enterprise Markets, including Argentina and Nigeria. Following the impairment charge, the carrying value of the Gillette
indefinite-lived intangible asset was equivalent to the estimated fair value as of December 31, 2023.
Based on our impairment testing performed during the three months ended December 31, 2024, the Gillette indefinite-lived intangible asset's fair value exceeds
its carrying value by greater than 10%. As of March 31, 2025, the carrying value of the Gillette indefinite-lived intangible asset was $12.8 billion. Adverse
changes in the business or in the macroeconomic environment, including foreign currency devaluation, increasing global inflation, or market contraction from
an economic recession, could reduce the underlying cash flows used to estimate the fair value of the Gillette indefinite-lived intangible asset and trigger a
further impairment charge.
The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales
growth rates (including residual growth rates), discount rate and royalty rates.
Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other
things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products
or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors could result in additional and prolonged
devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rates represent the expected rate at which the Gillette brand is
expected to grow beyond the shorter-term business planning period. The residual growth rates utilized in our fair value estimates are consistent with the brand
operating plans and approximate expected long-term category market growth rates. The residual growth rate depends on overall market growth rates, the
competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the residual growth rate could
be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased
competitive environment.
The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry
required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse
changes in the macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies
against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.
The royalty rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future
profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins.
We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended
December 31, 2024, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rate
to demonstrate the potential impacts to estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point
increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty rate.
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 10 of 48 --

Approximate Percent Change in Estimated Fair Value
+25 bps Discount Rate 	-25 bps Growth Rates 	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset 	(5)% 	(5)% 	(4)%
5. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted
average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings attributable
to Procter & Gamble by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of
stock options and other share-based awards based on the treasury stock method and the assumed conversion of preferred stock.
Net earnings per common share were calculated as follows:
CONSOLIDATED AMOUNTS 	Three Months Ended March 31 Nine Months Ended March 31
2025 	2024 	2025 	2024
Net earnings 	$ 	3,793 $ 	3,781 $ 	12,439 $ 	11,830
Less: Net earnings attributable to noncontrolling interests 	23 	27 	80 	88
Net earnings attributable to P&G 	3,769 	3,754 	12,359 	11,742
Less: Preferred dividends 	71 	69 	215 	209
Net earnings attributable to P&G available to common shareholders (Basic) 	$ 	3,698 $ 	3,685 $ 	12,144 $ 	11,533
SHARES IN MILLIONS
Basic weighted average common shares outstanding 	2,347.2 	2,360.5 	2,351.8 	2,359.5
Add effect of dilutive securities:
Convertible preferred shares 	70.7 	73.3 	71.3 	73.9
Stock options and other unvested equity awards 	31.9 	38.1 	34.9 	38.4
Diluted weighted average common shares outstanding 	2,449.8 	2,472.0 	2,458.0 	2,471.8
NET EARNINGS PER COMMON SHARE
Basic 	$ 	1.58 $ 	1.56 $ 	5.16 $ 	4.89
Diluted 	$ 	1.54 $ 	1.52 $ 	5.03 $ 	4.75
An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024.
Excludes approximately 8 million and 6 million for the three months ended March 31, 2025 and 2024 respectively, and 6 million for the nine months ended March 31, 2025
and 2024 respectively, of weighted average stock options outstanding because the exercise price of these options was greater than their average market value or their effect
was antidilutive.
6. Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit impacts:
Three Months Ended March 31 Nine Months Ended March 31
2025 	2024 	2025 	2024
Share-based compensation expense 	$ 	123 $ 	158 $ 	364 $ 	433
Net periodic benefit cost for pension benefits 	29 	52 	92 	160
Net periodic benefit (credit) for other retiree benefits 	(180) 	(156) 	(541) 	(467)
(1)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 11 of 48 --

10 The Procter & Gamble Company
7. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and
commodity prices. There have been no significant changes in our risk management policies or activities during the nine months ended March 31, 2025.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company
recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods
presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. Except for the impairment of the Gillette
indefinite-lived intangible asset discussed in Note 4, there were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis
during the nine months ended March 31, 2025 or during the fiscal year ended June 30, 2024.
Cash equivalents were $7.9 billion and $8.0 billion as of March 31, 2025 and June 30, 2024, respectively, and are classified as Level 1 within the fair value
hierarchy. The Company had no other material investments in debt or equity securities during the periods presented.
The fair value of long-term debt was $27.9 billion and $27.7 billion as of March 31, 2025 and June 30, 2024, respectively. This includes the current portion of
long-term debt instruments ($4.7 billion and $3.8 billion as of March 31, 2025 and June 30, 2024, respectively). Certain long-term debt (debt designated as a
fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We
consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar
instruments.
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of March 31, 2025 and June 30, 2024, are as follows:
Notional Amount 	Fair Value Asset 	Fair Value (Liability)
March 31, 2025 	June 30, 2024 	March 31, 2025 	June 30, 2024 	March 31, 2025 	June 30, 2024
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	3,034 $ 	2,993 $ 	— $ 	— $ 	(217) $ 	(325)
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	12,657 $ 	10,140 $ 	78 $ 	119 $ 	(124) $ 	(31)
TOTAL DERIVATIVES DESIGNATED AS
HEDGING INSTRUMENTS 	$ 	15,691 $ 	13,133 $ 	78 $ 	119 $ 	(340) $ 	(356)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	3,458 $ 	3,192 $ 	6 $ 	1 $ 	(7) $ 	(23)
TOTAL DERIVATIVES AT FAIR VALUE 	$ 	19,149 $ 	16,325 $ 	84 $ 	120 $ 	(347) $ 	(379)
The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the
fair value adjustment, was $2.8 billion and $2.7 billion as of March 31, 2025 and June 30, 2024, respectively. In addition to the foreign currency derivative
contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The
carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on
those instruments, was $10.9 billion and $11.9 billion as of March 31, 2025 and June 30, 2024, respectively. The increase in notional balance of the derivative
instruments designated as net investment hedges is primarily driven by the Company's decision to leverage favorable interest rate spreads in the foreign
currency swap market.
Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other
liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of
Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value
hierarchy.
Certain of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with
counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization
or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a liability position was $269
and $307 as of March 31, 2025 and June 30, 2024, respectively. The Company has not been required to post collateral as a result of these contractual features.
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 12 of 48 --

The Procter & Gamble Company 11
Before tax gains and losses on our financial instruments in hedging relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on Derivatives
Three Months Ended March 31 	Nine Months Ended March 31
2025 	2024 	2025 	2024
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	(473) $ 	269 $ 	(117) $ 	67
For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $60 and $53 for
the three months ended March 31, 2025 and 2024, respectively. The amount of gain excluded from effectiveness testing was $167 and $182 for the nine months ended
March 31, 2025 and 2024, respectively.
In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as
net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was $(436) and $262 for the three
months ended March 31, 2025 and 2024, respectively. The amount of gain/(loss) recognized in AOCI for such instruments was $(221) and $102 for the nine months
ended March 31, 2025 and 2024, respectively.
Amount of Gain/(Loss) Recognized in Earnings
Three Months Ended March 31 	Nine Months Ended March 31
2025 	2024 	2025 	2024
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	(2) $ 	(7) $ 	109 $ 	122
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	30 $ 	(84) $ 	(19) $ 	(27)
The gains/(losses) on the derivatives in fair value hedging relationships are fully offset by the mark-to-market impact of the related exposure. These are both
recognized in Interest expense. The gains/(losses) on derivatives not designated as hedging instruments are substantially offset by the currency mark-to-market
of the related exposure. These are both recognized in Selling, general and administrative expense (SG&A).
8. Accumulated Other Comprehensive Income/(Loss)
The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the
reclassifications out of AOCI by component:
Investment
Securities
Postretirement
Benefit Plans
Foreign Currency
Translation 	Total AOCI
Balance at June 30, 2024, net of tax 	$ 	10 $ 	613 $ 	(12,522) $ 	(11,900)
Other comprehensive income/(loss), before tax:
OCI before reclassifications 	3 	13 	(208) 	(192)
Amounts reclassified to the Consolidated Statement of Earnings 	— 	(62) 	752 	690
Total other comprehensive income/(loss), before tax 	3 	(49) 	544 	498
Tax effect 	— 	13 	79 	92
Total other comprehensive income/(loss), net of tax 	3 	(37) 	623 	590
Less: OCI attributable to noncontrolling interests, net of tax 	— 	2 	(4) 	(2)
Balance at March 31, 2025, net of tax 	$ 	13 $ 	574 $ 	(11,894) $ 	(11,307)
The below provides additional details on amounts reclassified from AOCI into the Consolidated Statement of Earnings:
• Postretirement benefit plan amounts are reclassified from AOCI into Other non-operating income/(expense), net and included in the computation of
net periodic postretirement costs.
• Foreign currency translation amounts are reclassified from AOCI into Other non-operating income/(expense), net. These amounts relate to
accumulated foreign currency translation losses recognized due to the substantial liquidation of operations in Argentina recorded in the period ended
September 30, 2024.
9. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust
and trade regulation, product liability, advertising, contracts, environmental, patent and trademark
(1) (2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 13 of 48 --

12 The Procter & Gamble Company
matters, labor and employment matters and tax. While considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of
the various lawsuits and claims will not materially affect our financial position, results of operations or cash flows.
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the
environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of
environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in about 70 countries and over 150 taxable jurisdictions and, at any point in time, has 30–40 jurisdictional audits underway at various
stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and may not
be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are
adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations. Such
adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2010 and forward. We are generally not able to reliably
estimate the timing and ultimate settlement amounts until the close of an audit. Based on information currently available, we anticipate over the next 12-month
period, audit activity could be completed related to uncertain tax positions in multiple jurisdictions for which we have accrued liabilities of approximately $50,
including interest and penalties.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2024.
10. Supplier Finance Programs
The Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a
Supply Chain Finance program (“SCF”) with several global financial institutions. Under SCF, the Company maintains an accounts payable system to facilitate
participating suppliers' ability to sell receivables from the Company to a SCF bank. These participating suppliers negotiate their sales of receivables
arrangements directly with the respective SCF bank. The Company is not party to those agreements, but the SCF banks allow the suppliers to utilize the
Company’s creditworthiness in establishing credit spreads and associated costs. Under this model, this arrangement generally provides the suppliers with more
favorable terms than they would be able to secure on their own. The Company has no economic interest in a supplier’s decision to sell a receivable. Once a
qualifying supplier chooses to participate in SCF, the supplier selects which individual Company invoices to sell to the SCF bank. The Company’s obligations
to its suppliers, including the amounts due and scheduled payment dates, are not impacted by the supplier’s decisions to finance amounts under these
arrangements. The Company does not provide any form of guarantee under these financing arrangements. Our payment terms for suppliers under this program
generally range from 60 to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our
Consolidated Balance Sheets, and the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount
due to suppliers participating in SCF and included in Accounts payable was approximately $5.6 billion as of March 31, 2025 and June 30, 2024.
11. Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including
manufacturing and workforce optimization. Before tax costs incurred under the ongoing program have generally ranged from $250 to $500 annually.
Consistent with our historical policies for restructuring-type activities, the restructuring program charges will be funded by and included within Corporate for
management and segment reporting.
In the fiscal year ended June 30, 2024, the Company started a limited market portfolio restructuring of its business operations, primarily in certain Enterprise
Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. During the period ended September 30, 2024, the
Company completed this limited market portfolio restructuring with the substantial liquidation of its operations in Argentina and recorded approximately
$0.8 billion after tax of incremental charges, comprised primarily of non-cash charges for accumulated foreign currency translation losses previously included
in Accumulated other comprehensive income/(loss). The total incremental restructuring charges incurred under the program beginning in the three-month
period ended December 31, 2023, through the three-month period ended September 30, 2024, were approximately $1.2 billion after tax.
For the three months ended March 31, 2025, the Company incurred total before tax charges of $55 including $23 in Costs of products sold, $26 in SG&A and
$6 in Other non-operating income/(expense). For the nine months ended March 31, 2025, the Company incurred charges of $987 including $91 in Costs of
products sold, $105 in SG&A and $791 in Other non-operating income/(expense).
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 14 of 48 --

The Procter & Gamble Company 13
The following table presents restructuring activity for the nine months ended March 31, 2025:
Separation Costs 	Asset-Related Costs 	Other Costs 	Total
RESERVE JUNE 30, 2024 	$ 	133 $ 	— $ 	32 $ 	166
Costs incurred for the six months ended December 31, 2024 	41 	39 	853 	933
Costs incurred for the three months ended March 31, 2025 	27 	8 	19 	55
Costs incurred for the nine months ended March 31, 2025 	68 	47 	872 	987
Costs paid/settled for the nine months ended March 31, 2025 	(126) 	(47) 	(842) 	(1,016)
RESERVE MARCH 31, 2025 	$ 	75 $ 	— $ 	62 $ 	138
Separation Costs
Employee separation costs relate to severance packages that are primarily voluntary and the amounts calculated are based on salary levels and past service
periods.
Asset-Related Costs
Asset-related costs consist of both asset write-downs and accelerated depreciation for manufacturing consolidations. Asset write-downs relate to the
establishment of a new fair value basis for assets held-for-sale or for disposal. These assets are written down to the lower of their current carrying basis or
amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out
of service prior to the end of their normal service period.
Other Costs
Other restructuring-type charges are incurred as a direct result of the restructuring plan. Such charges include accumulated foreign currency translation losses,
asset removal and termination of contracts.
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives
and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-
looking statements may appear throughout this report, including without limitation, the following sections: “Management's Discussion and Analysis,” “Risk
Factors” and "Notes 4 and 9 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and
uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to
update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial
risks, including foreign currency fluctuations, currency exchange, pricing controls or tariffs; (2) the ability to successfully manage local, regional or global
economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share
repurchases and dividend payments; (3) the ability to successfully manage uncertainties related to changing political and geopolitical conditions and potential
implications such as exchange rate fluctuations, market contraction, boycotts, sanctions, tariffs or other trade controls; (4) the ability to manage disruptions in
credit markets or to our banking partners or changes to our credit rating; (5) the ability to maintain key manufacturing and supply arrangements (including
execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to various
factors, including ones outside of our control, such as natural disasters, acts of war or terrorism or disease outbreaks; (6) the ability to successfully manage cost
fluctuations and pressures, including prices of commodities and raw materials and costs of labor, transportation, energy, pension and healthcare; (7) the ability
to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as
prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our
reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy, packaging
content, supply chain practices or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk
associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability
to rely on and maintain key company and third-party information and operational technology systems, networks and services and maintain the security and
functionality of such
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 15 of 48 --

14 The Procter & Gamble Company
systems, networks and services and the data contained therein; (12) the ability to successfully manage the demand, supply and operational challenges, as well
as governmental responses or mandates, associated with a disease outbreak, including epidemics, pandemics or similar widespread public health concerns; (13)
the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits,
evolving digital marketing and selling platform requirements and technological advances attained by, and patents granted to, competitors; (14) the ability to
successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and
financial objectives, without impacting the delivery of base business objectives; (15) the ability to successfully achieve productivity improvements and cost
savings and manage ongoing organizational changes while successfully identifying, developing and retaining key employees, including in key growth markets
where the availability of skilled or experienced employees may be limited; (16) the ability to successfully manage current and expanding regulatory and legal
requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition,
manufacturing processes, intellectual property, labor and employment, antitrust, privacy, cybersecurity and data protection, artificial intelligence, tax, the
environment, due diligence, risk oversight, accounting and financial reporting) and to resolve new and pending matters within current estimates; (17) the ability
to manage changes in applicable tax laws and regulations; and (18) the ability to successfully achieve our ambition of reducing our greenhouse gas emissions
and delivering progress towards our environmental sustainability priorities. A detailed discussion of risks and uncertainties that could cause actual results and
events to differ materially from those projected herein is included in the section titled "Economic Conditions and Uncertainties" and the section titled "Risk
Factors" (Part II, Item 1A) of this Form 10-Q.
Purpose, Approach and Non-GAAP Measures
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of
operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in
conjunction with, our Consolidated Financial Statements and accompanying Notes.
The MD&A is organized in the following sections:
• Overview
• Summary of Results – Nine Months Ended March 31, 2025
• Economic Conditions and Uncertainties
• Results of Operations – Three and Nine Months Ended March 31, 2025
• Segment Results – Three and Nine Months Ended March 31, 2025
• Liquidity and Capital Resources
• Measures Not Defined by U.S. GAAP
Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net
earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under U.S. GAAP,
consisting of organic sales growth, Core earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the
end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to
the most directly comparable U.S. GAAP measure.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the
availability and comparability of share and consumption information. References to market share and consumption in the MD&A are based on a combination
of vendor-purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the
percentage of sales of our products in dollar terms on a constant currency basis relative to all product sales in the category. The Company measures quarter and
fiscal year to date market share through the most recent period for which market share data is available, which typically reflects a lag time of one or two
months as compared to the end of the reporting period. Management also uses unit volume growth to evaluate drivers of changes in net sales. Organic volume
growth reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items, if applicable, and is
used to explain changes in organic sales. Certain columns and rows may not add due to rounding.
OVERVIEW
P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to
our consumers around the world. Our products are sold in about 180 countries and territories, primarily through mass merchandisers, e-commerce (including
social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores (including
airport duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to individual consumers. We have
on-the-ground operations in about 70 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products as well as retailers' private-label brands.

-- 16 of 48 --

The Procter & Gamble Company 15
Additionally, many of the product segments in which we compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-
tier products). We believe we are well positioned in the industry segments and markets in which we operate, often holding a leadership or significant market
share position.
The table below lists our reportable segments, including the product categories and brand composition within each segment.
Reportable Segments 	Product Categories (Sub-Categories) 	Major Brands
Beauty
Hair Care (Conditioners, Shampoos, Styling Aids, Treatments) Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Personal Care (Antiperspirants and Deodorants, Personal Cleansing) Native, Old Spice, Safeguard,
Secret
Skin Care (Facial Moisturizers, Cleaners and Treatments) 	Olay, SK-II
Grooming 	Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and
Post-Shave Products, Other Grooming) Braun, Gillette, Venus
Health Care
Oral Care (Toothbrushes, Toothpastes, Other Oral Care) 	Crest, Oral-B
Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care) Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) 	Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Baby, Feminine & Family Care
Baby Care (Baby Wipes, Taped Diapers and Pants) 	Luvs, Pampers
Feminine Care (Adult Incontinence, Menstrual Care) Always, Always Discreet,
Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) 	Bounty, Charmin, Puffs
Effective July 1, 2024, the Beauty reportable business segment separated Skin and Personal Care into individual operating segments, Skin Care and Personal Care. This
transition included separation of the management team, strategic decision-making, innovation plans, financial targets, budgets and management reporting.
Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater China, Latin America, Asia Pacific
and India, Middle East and Africa (IMEA).
The following table provides the percentage of net sales and net earnings by reportable business segment (excluding Corporate) for the three and nine months
ended March 31, 2025:
Three Months Ended March 31, 2025 	Nine Months Ended March 31, 2025
Net Sales 	Net Earnings 	Net Sales 	Net Earnings
Beauty 	18 % 	15 % 	18 % 	17 %
Grooming 	8 % 	9 % 	8 % 	9 %
Health Care 	15 % 	16 % 	15 % 	16 %
Fabric & Home Care 	35 % 	36 % 	35 % 	34 %
Baby, Feminine & Family Care 	24 % 	24 % 	24 % 	24 %
Total Company 	100 % 	100 % 	100 % 	100 %
RECENT DEVELOPMENTS
Limited Market Portfolio Restructuring
In the fiscal year ended June 30, 2024, the Company started a limited market portfolio restructuring of its business operations, primarily in certain Enterprise
Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. During the period ended September 30, 2024, the
Company completed this limited market portfolio restructuring with the substantial liquidation of its operations in Argentina and recorded incremental
restructuring charges of approximately $0.8 billion after tax, comprised primarily of non-cash charges for accumulated foreign currency translation losses
previously included in Accumulated other comprehensive income/(loss). The total incremental restructuring charges incurred under the program beginning in
the three-month period ended December 31, 2023, through the three-month period ended September 30, 2024, were approximately $1.2 billion after tax.
Consistent with our historical policies for ongoing restructuring-type activities, resulting charges were funded by and included
(1)
(1)
(1)

-- 17 of 48 --

16 The Procter & Gamble Company
within Corporate for segment reporting. Restructuring charges above the normal ongoing level of restructuring costs are reported as non-core charges. For more
details on the restructuring program, refer to Note 11 to the Consolidated Financial Statements.
SUMMARY OF RESULTS – Nine Months Ended March 31, 2025
The following are highlights of results for the nine months ended March 31, 2025, versus the nine months ended March 31, 2024:
• Net sales were $63.4 billion, a decrease of $112 million versus the prior year period. Net sales increased low single digits in Health Care, and decreased
low single digits in Baby, Feminine & Family Care and Beauty. Net sales in Grooming and Fabric & Home Care were unchanged. Organic sales, which
exclude the impacts of acquisitions and divestitures and foreign exchange, increased 2%. Organic sales increased low single digits in Health Care,
Grooming, Fabric & Home Care, Beauty and Baby, Feminine & Family Care.
• Net earnings were $12.4 billion, an increase of $609 million, or 5%, versus the prior year period due to the non-cash impairment charge of $1.3 billion
($1.0 billion after tax) on the Gillette intangible asset in the prior year, partially offset by higher restructuring charges in the current year of $0.8 billion
after tax related to the substantial liquidation of operations in certain Enterprise Markets, including Argentina.
• Net earnings attributable to Procter & Gamble were $12.4 billion, an increase of $617 million, or 5%, versus the prior year period.
• Diluted EPS increased 6% to $5.03 due to the increase in net earnings. Core EPS, which excludes incremental restructuring charges and the prior year
Gillette intangible asset impairment charge, increased 3% to $5.35.
• Operating cash flow was $12.8 billion. Adjusted free cash flow, which is defined as operating cash flow less capital expenditures and excluding payments
for the transitional tax resulting from the U.S. Tax Act, was $10.6 billion. Adjusted free cash flow productivity, which is defined as adjusted free cash flow
as a percentage of net earnings excluding a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of
operations in Argentina, was 80%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries worldwide, with more than half our sales generated outside the United States. Our
largest international markets are Greater China, the United Kingdom, Canada, Japan and Germany and collectively comprised approximately 20% of our net
sales in fiscal 2024. As a result, we are exposed to global macroeconomic factors, geopolitical tensions and government policies. We are exposed to various
risks due to economic, political and social instabilities, market volatility, natural disasters, debt and credit issues, currency controls, new or increased tariffs
(including any such tariffs between the U.S. and China or the U.S. and Canada), foreign exchange and interest rate changes. These risks can negatively impact
our net sales, net earnings and cash flows. For example, we are exposed to risks due to the ongoing war between Russia and Ukraine. Our Russia business
accounted for less than 2% of consolidated net sales and net earnings in the fiscal year ended June 30, 2024 and less than 2% of net assets as of June 30, 2024.
Foreign Exchange. We have significant exposure to exchange rate fluctuations, both due to translation and transaction exposures. Translation exposures arise
from measuring income statements of foreign subsidiaries with functional currencies other than the U.S. dollar. Transaction exposures involve impacts from 1)
input costs that are denominated in currencies other than the local reporting currency and 2) revaluation of working capital balances denominated in currencies
other than the functional currency. We have experienced significant foreign exchange impacts in the past due to the weakening of certain foreign currencies
versus the U.S. dollar, which have negatively impacted net sales, net earnings and cash flows. In response to the devaluation of foreign currencies (including
those deemed highly inflationary), any lags or inability (due to government restrictions) to implement price increases or the negative impacts of such actions on
product consumption may lead to a decline in our net sales, net earnings and cash flows.
Commodities and Supply Chain. Our costs are subject to fluctuations due to changes in commodity and input material prices, transportation costs,
inflationary impacts and productivity efforts. We have significant exposures to certain commodities and input materials, in particular certain oil-derived
materials like resins and paper-based materials like pulp. Volatility in the market price of commodities and input materials directly affects our costs.
Disruptions in manufacturing, supply and distribution operations can lead to increased costs. Legal or regulatory requirements and sustainability initiatives may
result in increased costs. We strive to implement, achieve and sustain cost improvement plans, including supply chain optimization and general overhead and
workforce optimization. Increased pricing in response to certain inflationary or cost increases may also offset portions of the cost impacts; however, such price
increases may negatively impact product consumption. If we are unable to manage cost impacts through pricing actions and consistent productivity
improvements, it may negatively impact our net sales, net earnings and cash flows.
Government Policies. We are exposed to changes in U.S. and foreign government legislative, regulatory or enforcement policies that can have a negative
impact on net sales, net earnings and cash flows. These include tax policy changes (both U.S. and foreign), including those resulting from the current work
being led by the OECD/G20 Inclusive Framework focused on

-- 18 of 48 --

The Procter & Gamble Company 17
"Addressing the Challenges of the Digitalization of the Economy”. Government controls such as currency exchanges, pricing and import authorizations as well
as government policies related to environmental and climate change matters and changes to international trade agreements, including tariffs, can also impact
our financial performance.
For additional information on risk factors that could impact our business results, please refer to Risk Factors in Part I, Item 1A of the Company's Form 10-K for
the fiscal year ended June 30, 2024.
RESULTS OF OPERATIONS – Three Months Ended March 31, 2025
The following discussion provides a review of results for the three months ended March 31, 2025, versus the three months ended March 31, 2024.
Three Months Ended March 31
Amounts in millions, except per share amounts 	2025 	2024 	% Chg
Net sales 	$ 	19,776 $ 	20,195 	(2)%
Operating income 	4,558 	4,460 	2%
Earnings before income taxes 	4,661 	4,592 	2%
Net earnings 	3,793 	3,781 	—%
Net earnings attributable to Procter & Gamble 	3,769 	3,754 	—%
Diluted net earnings per common share 	1.54 	1.52 	1%
Core net earnings per common share 	1.54 	1.52 	1%
Three Months Ended March 31
COMPARISONS AS A PERCENTAGE OF NET SALES 	2025 	2024 	Basis Pt Chg
Gross margin 	51.0 % 	51.2 % 	(20)
Selling, general & administrative expense 	27.9 % 	29.1 % 	(120)
Operating income 	23.0 % 	22.1 % 	90
Earnings before income taxes 	23.6 % 	22.7 % 	90
Net earnings 	19.2 % 	18.7 % 	50
Net earnings attributable to Procter & Gamble 	19.1 % 	18.6 % 	50
Net Sales
Net sales for the quarter decreased 2% to $19.8 billion. The decrease in net sales was due to unfavorable foreign exchange of 2% and unit volume decline of
1%, partially offset by higher pricing of 1%. Mix had a neutral impact on net sales. Excluding the impact of acquisitions and divestitures and foreign exchange,
organic sales increased 1% and organic volume was unchanged.
The following table summarizes key drivers of the change in net sales by reportable segment:
Net Sales Change Drivers 2025 vs. 2024 (Three Months Ended March 31)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures Foreign
Exchange 	Price 	Mix 	Other Net Sales
Growth
Beauty 	— % 	1 % 	(3) % 	3 % 	(2) % 	— % 	(2) %
Grooming 	1 % 	1 % 	(4) % 	2 % 	— % 	(1) % 	(2) %
Health Care 	(1) % 	(1) % 	(3) % 	1 % 	3 % 	— % 	— %
Fabric & Home Care 	(1) % 	— % 	(2) % 	— % 	— % 	— % 	(3) %
Baby, Feminine & Family Care 	(2) % 	(2) % 	(2) % 	— % 	1 % 	(1) % 	(4) %
Total Company 	(1)% 	— % 	(2)% 	1 % 	— % 	— % 	(2)%
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin decreased 20 basis points to 51.0% of net sales for the quarter. The decrease in gross margin was due to:
• 120 basis points of decline from unfavorable product mix,
• 40 basis points of product and packaging investments,
(1)
(2)
(1)
(2)

-- 19 of 48 --

18 The Procter & Gamble Company
• 30 basis points of higher commodity costs and
• 20 basis points of unfavorable foreign exchange impacts.
These impacts were partially offset by:
• 160 basis points of manufacturing productivity savings and
• 30 basis points of increase due to higher pricing.
Total SG&A spending decreased 6% to $5.5 billion versus the prior year period due to decreased marketing spending and overhead costs. SG&A as a
percentage of net sales decreased 120 basis points to 27.9% due to decreases in marketing spending and overhead costs as a percentage of net sales. Marketing
spending as a percentage of net sales decreased 30 basis points due to productivity savings. Overhead costs as a percentage of net sales decreased 70 basis
points as wage inflation and foreign exchange headwinds were more than offset by productivity savings, which includes adjustments to expected variable
compensation payouts. Other operating expenses as a percentage of net sales decreased 20 basis points due to favorable foreign exchange impacts.
Productivity-driven cost savings delivered 120 basis points of benefit to SG&A as a percentage of net sales.
Operating income increased $98 million, or 2%, to $4.6 billion and operating margin increased 90 basis points to 23.0% versus the prior year period primarily
due to decreased marketing spending and overhead costs, partially offset by the decrease in gross margin, the components of which are described above.
Non-Operating Expenses and Income
Interest expense was $217 million for the quarter, a decrease of $16 million versus the prior year period. Interest income was $111 million for the quarter, an
increase of $7 million versus the prior year period. Other non-operating income/(expense) was $210 million, which is a decrease of $50 million versus the prior
year period due to gains from the sale of minor brands in the prior year.
Income Taxes
The effective income tax rate for the three months ended March 31, 2025, was 18.6%, compared to 17.7% for the three months ended March 31, 2024. The
increase in the effective tax rate was primarily driven by lower excess tax benefits of share-based compensation.
Net Earnings
Net earnings were unchanged at $3.8 billion versus the prior year period due primarily to the increase in operating income, partially offset by the decrease in
other non-operating income and the increase in the effective tax rate. Foreign exchange had a negative impact of approximately $75 million on net earnings for
the quarter, including both transactional and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable
to Procter & Gamble were unchanged at $3.8 billion for the quarter. Diluted EPS increased 1% to $1.54 versus the prior year period.
RESULTS OF OPERATIONS – Nine Months Ended March 31, 2025
The following discussion provides a review of results for the nine months ended March 31, 2025, versus the nine months ended March 31, 2024.
Nine Months Ended March 31
Amounts in millions, except per share amounts 	2025 	2024 	% Chg
Net sales 	$ 	63,395 $ 	63,507 	—%
Operating income 	16,096 	14,660 	10%
Earnings before income taxes 	15,646 	14,891 	5%
Net earnings 	12,439 	11,830 	5%
Net earnings attributable to Procter & Gamble 	12,359 	11,742 	5%
Diluted net earnings per common share 	5.03 	4.75 	6%
Core net earnings per common share 	5.35 	5.19 	3%
Nine Months Ended March 31
COMPARISONS AS A PERCENTAGE OF NET SALES 	2025 	2024 	Basis Pt Chg
Gross margin 	51.8 % 	52.0 % 	(20)
Selling, general & administrative expense 	26.4 % 	26.8 % 	(40)
Operating income 	25.4 % 	23.1 % 	230
Earnings before income taxes 	24.7 % 	23.4 % 	130
Net earnings 	19.6 % 	18.6 % 	100
Net earnings attributable to Procter & Gamble 	19.5 % 	18.5 % 	100

-- 20 of 48 --

The Procter & Gamble Company 19
Net Sales
Net sales for the period were $63.4 billion, a $112 million decline versus the prior year period as a 1% decline from unfavorable foreign exchange was partially
offset by a 1% increase from higher pricing. Volume and mix were unchanged. Excluding the impact of acquisitions and divestitures and foreign exchange,
organic sales increased 2% and organic volume increased 1%.
The following table summarizes key drivers of the change in net sales by reportable segment:
Net Sales Change Drivers 2025 vs. 2024 (Nine Months Ended March 31)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange 	Price 	Mix 	Other
Net Sales
Growth
Beauty 	(1) % 	1 % 	(1) % 	2 % 	(2) % 	— % 	(2) %
Grooming 	3 % 	3 % 	(2) % 	1 % 	(1) % 	(1) % 	— %
Health Care 	(1) % 	— % 	(1) % 	1 % 	3 % 	— % 	2 %
Fabric & Home Care 	— % 	1 % 	(1) % 	— % 	1 % 	— % 	— %
Baby, Feminine & Family Care 	— % 	1 % 	(1) % 	— % 	— % 	— % 	(1) %
Total Company 	— % 	1 % 	(1)% 	1 % 	— % 	— % 	— %
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin decreased 20 basis points to 51.8% of net sales for the period. The decrease in gross margin was due to:
• 100 basis points of decline from unfavorable product mix,
• 40 basis points of product and packaging investments,
• 30 basis points of higher commodity costs,
• 20 basis points of higher transportation services and other costs and
• 10 basis points of unfavorable foreign exchange impacts.
These impacts were partially offset by:
• 160 basis points of manufacturing productivity savings and
• 20 basis points of increase due to higher pricing.
Total SG&A spending decreased 1% to $16.8 billion versus the prior year period due to higher foreign exchange transactional charges in the prior year period
and decreased overhead costs. SG&A as a percentage of net sales decreased 40 basis points to 26.4% due primarily to a decrease in other operating expenses as
a percentage of sales. Marketing spending as a percentage of net sales increased 10 basis points as the increase in marketing spending was partially offset by
productivity savings. Overhead costs as a percentage of net sales were unchanged as wage inflation was offset by productivity savings, which includes
adjustments to expected variable compensation payouts. Other operating expenses as a percentage of net sales decreased 40 basis points primarily driven by
favorable foreign exchange impacts. Productivity-driven cost savings delivered 100 basis points of benefit to SG&A as a percentage of net sales.
Operating income increased $1.4 billion, or 10%, to $16.1 billion and operating margin increased 230 basis points to 25.4% versus the prior year period due
primarily to the non-cash impairment charge of $1.3 billion ($1.0 billion after tax) on the Gillette intangible asset in the prior year.
Non-Operating Expenses and Income
Interest expense was $695 million for the period, a decrease of $10 million versus the prior year period. Interest income was $365 million for the period, a
decrease of $1 million versus the prior year period. Other non-operating income/(expense) was $(120) million, which is a decrease of $690 million versus the
prior year period primarily due to the non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in
Argentina recorded in the period ended September 30, 2024.
Income Taxes
The effective income tax rate for the nine months ended March 31, 2025, was 20.5%, compared to 20.6% for the nine months ended March 31, 2024. The
decrease in the effective tax rate was primarily driven by higher excess tax benefits of share-based compensation, favorable geographic mix impacts and
decreases from discrete impacts related to uncertain tax positions, partially offset by a 100 basis-point increase due primarily to the charge for accumulated
foreign currency translation losses due to the substantial liquidation of operations in Argentina.
(1)
(2)
(1)
(2)

-- 21 of 48 --

20 The Procter & Gamble Company
Net Earnings
Net earnings increased $609 million, or 5%, to $12.4 billion, as the increase in operating income, the components of which are described above, were partially
offset by the non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina recorded in the
period ended September 30, 2024. Foreign exchange had a negative impact of approximately $58 million on net earnings for the period, including both
transactional and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble
increased $617 million, or 5%, to $12.4 billion for the period. Diluted EPS increased 6% to $5.03 versus the prior year period due to the increase in net
earnings. Core EPS, which represents diluted EPS excluding charges for incremental restructuring and the impairment of the Gillette intangible asset, increased
3% to $5.35.
SEGMENT RESULTS – Three and Nine Months Ended March 31, 2025
The following discussion provides a review of results by reportable business segment. Analysis of the results for the three and nine months ended March 31,
2025, is provided based on a comparison to the three and nine months ended March 31, 2024. The primary financial measures used to evaluate segment
performance are net sales and net earnings. The table below provides supplemental information on net sales, earnings before income taxes and net earnings by
reportable business segment for the three and nine months ended March 31, 2025, versus the comparable prior year period (dollar amounts in millions):
Three Months Ended March 31, 2025
Net Sales
% Change
Versus Year Ago
Earnings/(Loss) Before
Income Taxes
% Change
Versus Year Ago 	Net Earnings/(Loss)
% Change
Versus Year Ago
Beauty 	$ 	3,490 	(2) % $ 	684 	(9) % $ 	539 	(8) %
Grooming 	1,505 	(2) % 	404 	7 % 	321 	6 %
Health Care 	2,880 	— % 	734 	7 % 	569 	8 %
Fabric & Home Care 	6,948 	(3) % 	1,642 	(3) % 	1,285 	(1) %
Baby, Feminine & Family Care 	4,755 	(4) % 	1,150 	(11) % 	880 	(12) %
Corporate 	198 	N/A 	48 	N/A 	200 	N/A
Total Company 	$ 	19,776 	(2)% $ 	4,661 	2 % $ 	3,793 	— %
Nine Months Ended March 31, 2025
Net Sales
% Change
Versus Year Ago
Earnings/(Loss) Before
Income Taxes
% Change
Versus Year Ago 	Net Earnings/(Loss)
% Change
Versus Year Ago
Beauty 	$ 	11,231 	(2) % $ 	2,746 	(12) % $ 	2,158 	(11) %
Grooming 	4,980 	— % 	1,493 	3 % 	1,206 	4 %
Health Care 	9,277 	2 % 	2,662 	6 % 	2,068 	7 %
Fabric & Home Care 	22,233 	— % 	5,709 	(1) % 	4,473 	1 %
Baby, Feminine & Family Care 	15,155 	(1) % 	3,997 	(4) % 	3,065 	(3) %
Corporate 	520 	N/A 	(961) 	N/A 	(531) 	N/A
Total Company 	$ 	63,395 	— % $ 	15,646 	5 % $ 	12,439 	5 %
Beauty
Three months ended March 31, 2025, compared with three months ended March 31, 2024
Beauty net sales decreased 2% to $3.5 billion, as unfavorable foreign exchange of 3% and unfavorable geographic mix of 2% were partially offset by positive
impacts of higher pricing of 3%. Unit volume was unchanged. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales
increased 2% and organic volume increased 1%. Global market share of the Beauty segment decreased 0.4 points.
• Hair Care net sales decreased mid-single digits. Negative impacts of unfavorable foreign exchange, divestitures and a unit volume decrease were partially
offset by positive impacts of favorable product mix and higher pricing (primarily in Latin America and North America). The volume decrease was driven
by a decline in Greater China (due to market contraction and the impact of divestitures), partially offset by growth in Latin America and North America
(both due to market growth). Organic sales were unchanged as a high single-digit growth in Latin America and a mid-single-digit growth in North America
were offset by a double-digit decline in Greater China. Global market share of the Hair Care category decreased 1 point.
• Personal Care net sales increased high single digits. Positive impacts of an increase in unit volume and higher pricing (primarily in North America) were
partially offset by negative impacts from geographic mix and unfavorable foreign

-- 22 of 48 --

The Procter & Gamble Company 21
exchange. The volume increase was driven by growth in Europe (due to distribution expansion and innovation), North America (due to innovation), and
Latin America (due to market growth). Organic sales increased high single digits due to a more than 20% growth in Europe, a mid-teens growth in Latin
America and a high single-digit growth in North America. Global market share of the Personal Care category increased 0.6 points.
• Skin Care net sales decreased mid-single digits. Negative impacts of a decrease in unit volume, unfavorable foreign exchange and unfavorable geographic
mix were partially offset by positive impacts from higher pricing (primarily in Greater China). The volume decrease was driven by North America and
Europe (both due to distribution losses). Organic sales decreased low single digits due to a low teens decline in North America and a high single-digit
decline in Asia Pacific, partially offset by a high single-digit growth in Greater China. Global market share of the Skin Care category decreased 0.8 points.
Net earnings decreased 8% to $539 million due to a decrease in net sales and a 110 basis-point decline in net earnings margin. Net earnings margin decreased
due to a decrease in gross margin and an increase in SG&A as a percentage of net sales. The gross margin decline was driven by unfavorable category and
geographic mix, partially offset by increased productivity savings. SG&A as a percentage of net sales increased due to increases in marketing, overhead
spending and higher foreign exchange transactional charges.
Nine months ended March 31, 2025, compared with nine months ended March 31, 2024
Beauty net sales decreased 2% to $11.2 billion, driven by unfavorable mix of 2% (due primarily to the decline of the super-premium SK-II brand, which has
higher than segment-average selling prices), unfavorable foreign exchange of 1% and a unit volume decrease of 1%, partially offset by the positive impacts of
higher pricing of 2%. Excluding the impact of acquisitions and divestitures and foreign exchange, organic volume and organic sales increased 1%. Global
market share of the Beauty segment decreased 0.2 points.
• Hair Care net sales decreased mid-single digits. Negative impacts of divestitures, declining unit volume and unfavorable foreign exchange were partially
offset by positive impacts of favorable product mix and higher pricing (primarily in Latin America and Europe). The decline in unit volume was driven by
a decline in Greater China (due to market contraction and the impact of divestitures), partially offset by growth in North America and Latin America (both
due to market growth). Organic sales increased low single digits due to a high single-digit growth in Latin America and a mid-single-digit growth in North
America, partially offset by a double-digit decline in Greater China. Global market share of the Hair Care category decreased 0.8 points.
• Personal Care net sales increased high single digits. Positive impacts of an increase in unit volume and higher pricing (primarily in North America) were
partially offset by unfavorable geographic mix and unfavorable foreign exchange. The volume increase was driven by growth in North America (due to
innovation), Europe (due to distribution expansion and innovation) and Latin America (due to market growth). Organic sales increased double digits due to
a more than 20% growth in Europe, a 20% growth in Latin America and a double-digit growth in North America, partially offset by a mid-single-digit
decline in Greater China. Global market share of the Personal Care category increased 0.6 points.
• Skin Care net sales decreased double digits. Negative impacts of a decrease in unit volume and unfavorable product mix (due primarily to the decline of
the super-premium SK-II brand, which has higher than category-average selling prices), were partially offset by higher pricing (primarily in Greater
China). The volume decrease was driven by declines in all regions, led by North America (due to distribution losses) and Greater China (due to market
contraction). Organic sales decreased double digits due to a high-teens decline in North America, a mid-teens decline in Asia Pacific and a mid-single-digit
decline in Greater China. Global market share of the Skin Care category decreased 0.6 points
Net earnings decreased 11% to $2.2 billion due to a decrease in net sales and a 190 basis-point decline in net earnings margin. Net earnings margin decreased
due to a decrease in gross margin and an increase in SG&A as a percentage of net sales. The gross margin decline was driven by unfavorable product mix (due
to the decline of the super-premium SK-II brand) and higher commodities, partially offset by increased productivity savings. SG&A as a percentage of net sales
increased due primarily to an increase in marketing and overhead spending.
Grooming
Three months ended March 31, 2025, compared with three months ended March 31, 2024
Grooming net sales decreased 2% to $1.5 billion as the negative impacts from unfavorable foreign exchange of 4% and divestitures of 1% were partially offset
by the positive impacts from higher pricing of 2% (driven primarily by Latin America, Europe and North America) and a unit volume increase of 1%. The
volume increase was driven by growth in IMEA (due to increased distribution) and Europe (due to market growth), partially offset by volume decline in Latin
America (due to competitive activity). Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 3% driven by high
single-digit growth in IMEA and low single-digit growth in North America and Europe. Global market share of the Grooming segment decreased 0.5 points.
Net earnings increased 6% to $321 million due to 160 basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross
margin and a decrease in SG&A as a percentage of net sales. The gross margin

-- 23 of 48 --

22 The Procter & Gamble Company
improvement was primarily driven by increased productivity savings and increased pricing, partially offset by unfavorable geographic mix. SG&A as a
percentage of net sales decreased due primarily to a reduction in marketing spending.
Nine months ended March 31, 2025, compared with nine months ended March 31, 2024
Grooming net sales were unchanged at $5.0 billion as the benefits of a 3% increase in unit volume and higher pricing of 1% (driven primarily by Latin America
and IMEA) were offset by unfavorable foreign exchange of 2%, unfavorable geographic mix of 1% and the negative impact from divestitures of 1%. The
volume increase was driven by growth in IMEA (due to increased distribution) and Europe (due to market growth). Excluding the impact of acquisitions and
divestitures and foreign exchange, Grooming organic sales increased 3% due to low-teens growth in IMEA, high single-digit growth in Asia Pacific and low
single-digit growth in Europe. Global market share of the Grooming segment increased 0.1 points.
Net earnings increased 4% to $1.2 billion due to a 90 basis-point increase in net earnings margin. Net earnings margin increased due to a decrease in SG&A as
a percentage of net sales, an increase in gross margin and a lower effective tax rate. The gross margin increase was driven primarily by productivity savings,
partially offset by unfavorable geographic mix. SG&A as a percentage of net sales decreased due to higher foreign exchange transactional charges in the prior
year period. The lower effective tax rate was driven by favorable geographic mix.
Health Care
Three months ended March 31, 2025, compared with three months ended March 31, 2024
Health Care net sales were unchanged at $2.9 billion as the benefits of favorable product mix of 3% and higher pricing of 1% were offset by unfavorable
foreign exchange impacts of 3% and a 1% decrease in unit volume. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales
increased 4%. Global market share of the Health Care segment increased 0.3 points.
• Oral Care net sales decreased low single digits driven by a unit volume decline and negative impacts of unfavorable foreign exchange, partially offset by
positive impacts of favorable product mix (due to growth of power brushes and premium paste, which have higher than category-average selling prices).
The unit volume decrease was due to declines in all regions, led by Greater China (due to market contraction and competitive activity) and IMEA (due to
share losses). Organic sales increased low single digits driven by a mid-single-digit increase in Europe, partially offset by a mid-teens decrease in Greater
China. Global market share of the Oral Care category increased 0.1 points.
• Personal Health Care net sales increased mid-single digits driven by a unit volume increase and the positive impact of higher pricing (driven by Latin
America and Europe), partially offset by the negative impact of unfavorable foreign exchange. The unit volume increase was primarily due to growth in
North America (due to the later peak in the respiratory season) and IMEA (due to innovation). Organic sales increased high single digits driven by low-
teens growth in Latin America and high single-digit growth in North America. Global market share of the Personal Health Care category increased 0.4
points.
Net earnings increased 8% to $569 million due to a 140 basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross
margin, a decrease in SG&A as a percentage of net sales and a lower effective tax rate. The gross margin increase was driven primarily by productivity savings
and higher pricing, partially offset by unfavorable geographic mix. SG&A as a percentage of net sales decreased due to a decline in marketing spending. The
lower effective tax rate was driven by favorable geographic mix.
Nine months ended March 31, 2025, compared with nine months ended March 31, 2024
Health Care net sales increased 2% to $9.3 billion driven by favorable geographic and product mix of 3% and higher pricing of 1%, partially offset by
unfavorable foreign exchange of 1% and a 1% decrease in unit volume. Excluding the impact of acquisitions and divestitures and foreign exchange, organic
sales increased 3% and organic volume was unchanged. Global market share of the Health Care segment increased 0.2 points.
• Oral Care net sales increased low single digits due to the positive impacts of favorable product mix (due to growth of premium paste and power brushes,
which have higher than category-average selling prices), partially offset by a decline in unit volume and unfavorable foreign exchange. The unit volume
decrease was due to a decline in Greater China (due to market contraction and increased competitive activity) and IMEA (due to share losses), partially
offset by growth in North America (due to market growth and innovation). Organic sales also increased low single digits due to a high single-digit increase
in Europe and a low single-digit increase in North America, partially offset by mid-teens decreases in Greater China and IMEA. Global market share of the
Oral Care category increased 0.1 points.
• Personal Health Care net sales increased low single digits due to a unit volume increase and the positive impacts of higher pricing (driven by Latin
America and Europe) and favorable geographic mix, partially offset by the negative impacts of unfavorable foreign exchange. The increase in unit volume
was driven by growth in North America (due to distribution gains), partially offset by a decline in IMEA (due to market contraction and increased
competitive activity). Organic sales increased mid-single digits due to a high single-digit growth in Latin America and a mid-single-digit growth in both
North America and Europe. Global market share of the Personal Health Care category increased 0.2 points.

-- 24 of 48 --

The Procter & Gamble Company 23
Net earnings increased 7% to $2.1 billion due to net sales growth and a 110 basis-point increase in net earnings margin. Net earnings margin increased due to
an increase in gross margin and a decrease in SG&A as a percentage of net sales. The gross margin increase was driven by productivity savings, partially offset
by unfavorable geographic mix. SG&A as a percentage of net sales decreased due to decreased marketing spending.
Fabric & Home Care
Three months ended March 31, 2025, compared with three months ended March 31, 2024
Fabric & Home Care net sales decreased 3% to $6.9 billion driven by unfavorable foreign exchange of 2% and a unit volume decrease of 1%. Excluding the
impact of foreign exchange and acquisitions and divestitures, organic sales and organic volume were unchanged. Global market share of the Fabric & Home
Care segment increased 0.1 points.
• Fabric Care net sales decreased low single digits driven by unfavorable foreign exchange. Unit volume was unchanged as growth in Latin America (due to
market growth) and IMEA (due to market growth) was offset by a decline in North America (due to retail inventory reduction). Organic sales were
unchanged as the impact of a mid-single-digit growth in Latin America and a low single-digit growth in Europe was offset by the impact of a high single-
digit decline in IMEA and a low single-digit decline in North America. Global market share of the Fabric Care category decreased 0.4 points.
• Home Care net sales decreased low single digits driven by a unit volume decrease and unfavorable foreign exchange, partially offset by favorable premium
product mix. The decrease in volume was due primarily to a decline in Europe (due to increased competitive activity). Organic sales decreased low single
digits driven by a low single-digit decline in Europe, partially offset by a low single-digit growth in North America. Global market share of the Home Care
category increased 0.7 points.
Net earnings decreased 1% to $1.3 billion as the decrease in net sales was partially offset by a 40 basis-point increase in net
earnings margin. Net earnings margin increased due to a decrease in SG&A as a percentage of net sales and a lower effective tax rate, partially offset by a
decrease in gross margin. The gross margin decrease was driven by unfavorable geographic and product mix, partially offset by productivity savings. SG&A as
a percentage of net sales decreased due to a decrease in marketing spending. The lower effective tax rate was driven by favorable geographic mix.
Nine months ended March 31, 2025, compared with nine months ended March 31, 2024
Fabric & Home Care net sales were unchanged at $22.2 billion as favorable product mix of 1% was offset by unfavorable foreign exchange of 1%. Unit
volume was unchanged. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 2% and organic volume increased
1%. Global market share of the Fabric & Home Care segment increased 0.1 points.
• Fabric Care net sales decreased low single digits driven by an unfavorable foreign exchange impact, partially offset by the positive impact of favorable
premium product mix. Unit volume was unchanged as growth in Europe (due to innovation) and North America (due to market growth) was offset by
declines in Latin America and Asia Pacific (both due to share losses). Organic sales increased low single digits driven by a mid-single-digit increase in
Europe and a low single-digit increase in North America, partially offset by a double-digit decrease in IMEA. Global market share of the Fabric Care
category decreased 0.1 points.
• Home Care net sales increased low single digits driven by a unit volume increase and favorable premium product mix, partially offset by the impact of
unfavorable foreign exchange. The increase in volume was driven by growth in North America (due to innovation). Organic sales increased low single
digits driven by mid-single-digit growth in North America and low single-digit growth in Europe. Global market share of the Home Care category
increased 0.4 points.
Net earnings increased 1% to $4.5 billion due to a 10 basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross
margin and a lower effective tax rate, partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by increased
productivity savings, partially offset by unfavorable geographic and product mix. SG&A as a percentage of net sales increased due to an increase in marketing
and overhead spending, partially offset by higher foreign exchange transactional charges in the prior year period. The lower effective tax rate was driven by
favorable geographic mix.
Baby, Feminine & Family Care
Three months ended March 31, 2025, compared with three months ended March 31, 2024
Baby, Feminine & Family Care net sales decreased 4% to $4.8 billion driven by a 2% decrease in unit volume and a 2% decline from unfavorable foreign
exchange, partially offset by favorable geographic and product mix of 1%. Excluding the impacts of foreign exchange and acquisitions and divestitures,
organic sales decreased 1%. Global market share of the Baby, Feminine & Family Care segment decreased 0.3 points.
• Baby Care net sales decreased mid-single digits. Negative impacts of a decrease in unit volume, unfavorable foreign exchange and divestitures were
partially offset by positive impacts of favorable geographic and product mix (due to a higher proportion of premium diapers, which have higher than
category-average selling prices). The unit volume decline was driven by IMEA (due to competitive activity), North America (due to distribution loss and
competitive activity) and

-- 25 of 48 --

24 The Procter & Gamble Company
Latin America (due to the impact of divestitures and pricing). Organic sales decreased low single digits driven by a low-teens decline in Asia Pacific and a
double-digit decline in IMEA, partially offset by a low-teens increase in Greater China. Global market share of the Baby Care category decreased 0.1
points.
• Feminine Care net sales decreased low single digits driven by a unit volume decline and negative impacts of unfavorable foreign exchange, partially offset
by positive impacts of favorable geographic mix. The unit volume decrease was primarily driven by declines in Greater China (due to market contraction
and competitive activity) and Latin America (due to share losses), partially offset by growth in North America (due to market growth). Organic sales were
unchanged as the impact of a mid-single-digit growth in North America was offset by double-digit declines in Greater China and Latin America. Global
market share of the Feminine Care category decreased 0.3 points.
• Net sales in Family Care, which is predominantly a North America business, decreased low single digits driven by a decrease in unit volume (due to retail
inventory reduction and competitive activity), lower pricing (due to merchandising investments) and unfavorable product mix (due to growth of larger
pack sizes, with lower than category-average selling prices). Organic sales also decreased low single digits. North America market share of the Family
Care category decreased 0.4 points.
Net earnings decreased 12% to $880 million due to a decrease in net sales and a 170 basis-point decline in net earnings margin. Net earnings margin decreased
due to a decline in gross margin and an increase in SG&A as a percentage of net sales. Gross margin decreased primarily due to higher commodity costs and
unfavorable category mix. SG&A as a percentage of net sales increased due to the negative scale effects of the net sales decrease.
Nine months ended March 31, 2025, compared with nine months ended March 31, 2024
Baby, Feminine & Family Care net sales decreased 1% to $15.2 billion driven by unfavorable foreign exchange of 1%. Unit volume was unchanged. Excluding
the impacts of foreign exchange and acquisitions and divestitures, organic sales and organic volume increased 1%. Global market share of the Baby, Feminine
& Family Care segment decreased 0.2 points.
• Baby Care net sales decreased mid-single digits. Negative impacts of a decrease in unit volume, lower pricing (driven by investments in North America
and Europe), unfavorable foreign exchange and divestitures were partially offset by favorable geographic and product mix (due to a higher proportion of
premium diapers, which have higher than category-average selling prices). The unit volume decline was across most regions led by IMEA (due to
competitive activity), Asia Pacific (due to market contraction) and Latin America (due to the impact of divestitures). Organic sales decreased low single
digits primarily driven by a double-digit decline in IMEA and a mid-single-digit decline in Europe. Global market share of the Baby Care category
decreased 0.2 points.
• Feminine Care net sales were unchanged. Positive impacts of favorable geographic mix were offset by negative impacts of a decrease in unit volume and
unfavorable foreign exchange. The unit volume decrease was primarily driven by declines in Greater China (due to market contraction and competitive
activity) and Latin America (due to share losses), partially offset by growth in North America (due to market growth). Organic sales increased low single
digits driven by a mid-single-digit growth in North America, partially offset by a mid-single-digit decline in Greater China. Global market share of the
Feminine Care category decreased 0.4 points.
• Net sales in Family Care, which is predominantly a North America business, increased low single digits driven by an increase in unit volume (due to retail
inventory build, partially offset by competitive activity), partially offset by lower pricing (due to merchandising investments). Excluding the impact of
foreign exchange, organic sales increased mid-single digits. North America market share of the Family Care category decreased 0.1 points.
Net earnings decreased 3% to $3.1 billion due to a decrease in net sales and a 60 basis-point decline in net earnings margin. Net earnings margin decreased due
to a decrease in gross margin, partially offset by a decrease in SG&A as a percentage of net sales. Gross margin decreased primarily due to higher commodity
costs and unfavorable category mix, partially offset by productivity savings. SG&A as a percentage of net sales decreased due to higher foreign exchange
transactional charges in the prior year period and a reduction in marketing spending.
Corporate
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include but are not limited to incidental
businesses managed at the corporate level, gains and losses related to certain divested brands or businesses, impacts from various financing and investing
activities, impacts related to employee benefits, asset impairments and restructuring activities including manufacturing and workforce optimization. Corporate
also includes reconciling items to adjust the accounting policies used within the reportable segments to U.S. GAAP. The most notable ongoing reconciling item
is income taxes, which adjusts the blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.
For the three months ended March 31, 2025, Corporate net sales increased $70 million to $198 million due to an increase in net sales of incidental businesses
managed at the corporate level. Corporate net earnings increased $132 million to $200 million for the quarter due primarily to adjustments to expected variable
compensation payouts.

-- 26 of 48 --

The Procter & Gamble Company 25
For the nine months ended March 31, 2025, Corporate net sales increased $122 million to $520 million due to an increase in net sales of incidental businesses
managed at the corporate level. Corporate net earnings increased $783 million to a loss of $531 million due primarily to the non-cash impairment charge of
$1.3 billion ($1.0 billion after tax) on the Gillette intangible asset in the prior year, partially offset by incremental restructuring charges in the current year,
comprised primarily of accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
Operating cash flow was $12.8 billion fiscal year to date, a decrease of $1.3 billion versus the prior year period. Net earnings, adjusted for non-cash items
(depreciation and amortization, share-based compensation expense, deferred income taxes and loss on sale of assets), generated $15.9 billion of operating cash
flow. Working capital and other impacts used $3.1 billion of cash in the period primarily driven by the payment of the transitional tax related to the U.S. Tax
Act, a reduction in postretirement benefit and compensation accruals, a reduction in accrued marketing expense and a reduction in accounts payable. Days sales
outstanding were flat. Days inventory on hand increased by four days driven by higher inventory for new product initiatives and increased safety stock levels.
Investing Activities
Investing activities used $2.8 billion of cash fiscal year to date primarily driven by capital expenditures.
Financing Activities
Financing activities used $10.4 billion of net cash fiscal year to date, mainly due to dividends to shareholders and treasury stock purchases, partially offset by
the impact of stock options and other and a net debt increase.
As of March 31, 2025, our current liabilities exceeded current assets by $9.8 billion. We anticipate being able to support our short-term liquidity and operating
needs largely through cash generated from operations. We have strong short- and long-term debt ratings that have enabled and should continue to enable us to
refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In addition, we have agreements with a diverse group of
financial institutions that, if needed, should provide sufficient funding to meet short-term financing requirements.
MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most
closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e., trends excluding non-recurring
or unusual items) and results and provide a supplemental measure of period-to-period results. The non-GAAP measures described below are used by
management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors, as
they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management.
These measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not
intended to be considered by the user in place of the related GAAP measures but rather as supplemental information to our business results. These non-GAAP
measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth. Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign
exchange from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by
providing sales growth on a consistent basis. This measure is used in assessing the achievement of management goals for at-risk compensation.

-- 27 of 48 --

26 The Procter & Gamble Company
The following tables provide a numerical reconciliation of organic sales growth to reported net sales growth:
Three Months Ended March 31, 2025 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact/Other 	Organic Sales Growth
Beauty 	(2) % 	3 % 	1 % 	2 %
Grooming 	(2) % 	4 % 	1 % 	3 %
Health Care 	— % 	3 % 	1 % 	4 %
Fabric & Home Care 	(3) % 	2 % 	1 % 	— %
Baby, Feminine & Family Care 	(4) % 	2 % 	1 % 	(1) %
Total Company 	(2)% 	2 % 	1 % 	1 %
Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to
organic sales.
Nine Months Ended March 31, 2025 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact/Other 	Organic Sales Growth
Beauty 	(2) % 	1 % 	2 % 	1 %
Grooming 	— % 	2 % 	1 % 	3 %
Health Care 	2 % 	1 % 	— % 	3 %
Fabric & Home Care 	— % 	1 % 	1 % 	2 %
Baby, Feminine & Family Care 	(1) % 	1 % 	1 % 	1 %
Total Company 	— % 	1 % 	1 % 	2 %
Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to
organic sales.
Adjusted free cash flow. Adjusted free cash flow is defined as operating cash flow less capital expenditures and excluding payments for the transitional tax
resulting from the U.S. Tax Act. Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance
and asset expansion. We view adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for
dividends, share repurchases, acquisitions and other discretionary investments.
The following table provides a numerical reconciliation of adjusted free cash flow ($ millions):
Nine Months Ended March 31, 2025
Operating Cash Flow 	Capital Spending 	U.S. Tax Act Payments 	Adjusted Free Cash Flow
$ 	12,832 $ 	(2,777) $ 	562 $ 	10,617
Adjusted free cash flow productivity. Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings excluding a non-
cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina. We view adjusted free cash flow
productivity as a useful measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used by management in
making operating decisions, in allocating financial resources and for budget planning purposes. This measure is also used in assessing the achievement of
management goals for at-risk compensation.
The following table provides a numerical reconciliation of adjusted free cash flow productivity ($ millions):
Nine Months Ended March 31, 2025
Adjusted Free Cash Flow 	Net Earnings
Adjustments to
Net Earnings
Net Earnings
as Adjusted
Adjusted Free Cash
Flow Productivity
$ 	10,617 $ 	12,439 $ 	752 $ 	13,191 	80 %
Adjustments to Net earnings relate to a non-cash charge for accumulated foreign currency translation losses due to the substantial liquidation of operations in Argentina.
Core EPS. Core EPS is a measure of the Company's diluted EPS excluding items that are not judged by management to be part of the Company's sustainable
results or trends. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used
in assessing the achievement of management goals for at-risk compensation. The Core earnings measures included in the following reconciliation tables refer
to the equivalent GAAP measures adjusted as applicable for the following items:
• Incremental restructuring: The Company has historically had an ongoing level of restructuring activities of approximately $250 - $500 million before
tax. In the fiscal year ended June 30, 2024, the Company started a limited market portfolio restructuring of its business operations, primarily in certain
Enterprise Markets, including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. During the period ended
September 30,
(1)
(1)
(1)
(1)
(1)
(1)

-- 28 of 48 --

The Procter & Gamble Company 27
2024, the Company completed this limited market portfolio restructuring with the substantial liquidation of its operations in Argentina. The adjustment
to Core earnings includes the restructuring charges that exceed the normal, recurring level of restructuring charges.
• Intangible asset impairment: In the fiscal year ended June 30, 2024, the Company recognized a non-cash, after-tax impairment charge of $1.0 billion
($1.3 billion before tax) to adjust the carrying value of the Gillette intangible asset acquired as part of the Company's 2005 acquisition of The Gillette
Company.
We do not view the above items to be part of our sustainable results, and their exclusion from core earnings measures provides a more comparable measure of
year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Three Months Ended
March 31, 2025 	Three Months Ended March 31, 2024
Amounts in millions except per share amounts
As Reported
(GAAP)
As Reported
(GAAP)
Incremental
Restructuring
Core
(Non-GAAP)
Cost of products sold 	$ 	9,694 $ 	9,855 $ 	(13) $ 	9,842
Selling, general and administrative expense 	5,524 	5,880 	3 	5,883
Operating income 	4,558 	4,460 	10 	4,471
Income taxes 	868 	812 	— 	812
Net earnings attributable to P&G 	3,769 	3,754 	10 	3,763
Core EPS
Diluted net earnings per common share 	$ 	1.54 $ 	1.52 $ 	— $ 	1.52
For the three months ended March 31, 2025, there were no adjustments to or reconciling items for Core EPS.
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE IN CURRENT YEAR REPORTED (GAAP) MEASURES VERSUS PRIOR
YEAR NON-GAAP (CORE) MEASURES
Core net earnings attributable to P&G 	— %
Core EPS 	1 %
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Nine Months Ended March 31, 2025
Amounts in millions except per share amounts 	As Reported (GAAP) 	Incremental Restructuring
Core
(Non-GAAP)
Cost of products sold 	$ 	30,533 $ 	20 $ 	30,554
Selling, general and administrative expense 	16,765 	(25) 	16,740
Operating income 	16,096 	5 	16,101
Other non-operating income/(expense), net 	(120) 	789 	669
Income taxes 	3,207 	(7) 	3,199
Net earnings attributable to P&G 	12,359 	801 	13,160
Core EPS
Diluted net earnings per common share 	$ 	5.03 $ 	0.33 $ 	5.35
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
Core net earnings attributable to P&G 	3 %
Core EPS 	3 %
(1)
(2)
(1)
(2)
(1)
(1)

-- 29 of 48 --

28 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Nine Months Ended March 31, 2024
Amounts in millions except per share amounts 	As Reported (GAAP) Incremental
Restructuring 	Intangible Impairment Core
(Non-GAAP)
Cost of products sold 	$ 	30,500 $ 	(25) $ 	— $ 	30,475
Selling, general and administrative expense 	17,006 	(4) 	— 	17,002
Operating income 	14,660 	29 	1,341 	16,031
Income taxes 	3,061 	(20) 	315 	3,357
Net earnings attributable to P&G 	11,742 	49 	1,026 	12,817
Core EPS
Diluted net earnings per common share 	$ 	4.75 $ 	0.02 $ 	0.42 $ 	5.19
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the Company’s exposure to market risk since June 30, 2024. Additional information can be found in Note 9, Risk
Management Activities and Fair Value Measurements, of the Company's Form 10-K for the fiscal year ended June 30, 2024.
Item 4. 	Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s Chairman of the Board, President and Chief Executive Officer, Jon R. Moeller, and the Company’s Chief Financial Officer, Andre Schulten,
performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of
1934 (Exchange Act)) as of the end of the period covered by this report.
Messrs. Moeller and Schulten have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be
disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in SEC
rules and forms, and (2) accumulated and communicated to our management, including Messrs. Moeller and Schulten, to allow their timely decisions regarding
required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended March 31, 2025, that have
materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. 	Legal Proceedings
The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and
tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental
authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold ($1
million or more).
There were no material changes during the quarter ended March 31, 2025, to our disclosure in Part I, Item 3, “Legal Proceedings” of our Form 10-K for the
fiscal year ended June 30, 2024. There were no relevant matters to disclose under this Item for this period.
Item 1A. 	Risk Factors
For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2024.
(1)
(1)

-- 30 of 48 --

The Procter & Gamble Company 29
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of
Shares Purchased
Average Price Paid per
Share
Total Number of Shares Purchased as Part
of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares That May
Yet Be Purchased Under Our Share Repurchase
Program
1/01/2025 - 1/31/2025 	— $ 	— 	—
2/01/2025 - 2/28/2025 	4,152,570 	168.57 	4,152,570
3/01/2025 - 3/31/2025 	3,812,329 	170.50 	3,812,329
Total 	7,964,899 	$169.49 	7,964,899 	(3)
All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to
satisfy tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third
party and does not repurchase stock in connection with cashless exercises.
Average price paid per share for open market transactions excludes commission.
In accordance with the repurchase program announced on July 30, 2024, the Company reaffirmed in its earnings release on April 24, 2025, that it expects to reduce
outstanding shares through direct share repurchases at a value of $6 to $7 billion in fiscal year 2025, notwithstanding any purchases under the Company's compensation and
benefit plans. Purchases may be made in the open market and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior
notice. The share repurchases are authorized pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of
operating cash flows and issuance of debt.
Item 5. 	Other Information
During the three months ended March 31, 2025, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule
10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.
(1) 	(2) 	(3)
(3)
(3)
(3)
(1)
(2)
(3)
Amounts in millions of dollars unless otherwise specified.

-- 31 of 48 --

30 The Procter & Gamble Company
Item 6. 	Exhibits
3.1 Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the
Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June
30, 2016)
3.2 Regulations (as approved by the Board of Directors on December 13, 2022, pursuant to authority granted by shareholders at the annual
meeting on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company’s Current Report on Form 8-K filed
December 13, 2022)
4.1 Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (Incorporated
by reference to Exhibit (4-1) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015)
10.1 Company's Form of Separation Agreement & Release *+
31.1 Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 Section 1350 Certifications – Chief Executive Officer +
32.2 Section 1350 Certifications – Chief Financial Officer +
101.SCH 	Inline XBRL Taxonomy Extension Schema Document
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF 	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
* Compensatory plan or arrangement
+ Filed herewith
Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
April 24, 2025 	/s/ MATTHEW W. JANZARUK
Date 	(Matthew W. Janzaruk)
Senior Vice President - Chief Accounting Officer
(Principal Accounting Officer)
(1)
(1)
(1)
(1)
(1)
(1)

-- 32 of 48 --

Exhibit (10.1)
Company’s Form of Separation Agreement & Release

-- 33 of 48 --

SEPARATION AGREEMENT & RELEASE
To: «Employee_Name»
Date: «Actual_Offer_Date»
«Company» (“P&G”) is willing to provide you with certain assistance following your employment separation from the Company. The following,
which is subject to your approval, sets forth our proposed agreement to do so. Your receipt of the benefits described below is conditioned upon
your accepting, and abiding by, the terms of this Agreement.
Employment Separation Date: 	Your Employment Separation Date will be «Exit_Date», referred to as your “Employment Separation
Date.” You understand and agree that if P&G determines that you engaged in misconduct during your
employment, or if you fail to perform your work and responsibilities in a satisfactory manner up to and
including your Employment Separation Date, P&G may terminate your employment immediately and
will not provide, nor be obligated to provide, the payment(s) and other benefits described in this
Agreement. Otherwise, unless noted below, your pay and benefits will cease as of your Employment
Separation Date.
Separation Payment: 	As soon as administratively practical after your Employment Separation Date, P&G will provide you
with a Separation Payment of $«Total_Amount», less legally required withholdings and deductions. In
no event will payment be made before expiration of the seven-day revocation period discussed below or
later than the March 15th of the year following the year which includes your Employment Separation
Date. The Separation Payment will be the only monetary assistance P&G provides upon your
separation. Other resources may be available to you as a participant in general compensation and
benefit plans, which it will be your responsibility to identify and make any necessary arrangements
upon separation.
Amounts you owe to P&G as of your Employment Separation Date, including, but not limited to, wage
and/or benefit overpayments and unpaid loans, will also be deducted from the Separation Payment.

-- 34 of 48 --

Payment for Unvested PST: 	If you are not fully-vested in the Procter & Gamble Profit Sharing Trust and Employee Stock
Ownership Plan (“PST”) as of your Employment Separation Date, as soon as administratively practical
after your Employment Separation Date, but no later than the March 15 of the year following the year
which includes your Employment Separation Date, you will receive a lump sum payment in an amount
substantially equivalent to the non-vested credits in your account in the PST.
STAR Awards: 	As of your Employment Separation Date, if you were otherwise eligible for a STAR award and you
worked at least 28 days (4 calendar weeks) during that fiscal year, you will receive a pro-rated STAR
award for that fiscal year. Your STAR award will be pro-rated by dividing the number of calendar days
during the fiscal year from July 1 through your Employment Separation Date by 365. However, if you
are on a leave of absence prior to your Employment Separation Date, your first day out of the office will
be used to calculate the pro-rated percent.
Your STAR award will be paid in cash in the September (but no later than September 15th) immediately
following the end of the fiscal year in which you terminate. Any current election for Stock Options will
be reverted to cash.
Equity Awards: 	Your separation will be treated as a Special Separation for purposes of any outstanding equity awards
granted under the Procter & Gamble 2009 Stock and Incentive Compensation Plan or the Gillette
Company 2004 Long-Term Incentive Plan and, as a result, you will retain the awards subject to the
original terms and conditions of the awards. You will also retain awards granted under the Procter &
Gamble 2014 Stock & Incentive Compensation Plan and the Procter & Gamble 2019 Stock & Incentive
Compensation Plan subject to the terms and conditions of those Awards. For any award granted under
the Long-Term Incentive Program (LTIP) and/or Performance Stock Program (PSP) within one year
prior to the separation date, that award will be prorated based on the number of days worked in the 12
months following the October grant date, with a minimum of 28 days worked beyond the October grant
date.
This Separaon Leer & Release does not alter the rights and obligaons that you may have under the
Procter & Gamble 2019 Stock & Incenve Compensaon Plan, the Procter & Gamble 2014 Stock &
Incenve Compensaon Plan, the Procter & Gamble 2009 Stock and Incenve Compensaon Plan, and
the Gillee Company 2004 Long-Term Incenve Plan.
th

-- 35 of 48 --

Current Health, Dental, and Life
Insurance Benefits:
If you are enrolled in P&G’s active health (including medical, prescription drug, and EAP coverage),
active dental, and company-paid life insurance coverage, that coverage will continue under the same
terms until «Benefits_End_Date».
If you continue to receive P&G active health coverage during the extension of benefits period, that
coverage will be impacted if you (or your eligible dependents, including but not limited to your spouse
or domestic partner) are or become eligible for Medicare. For more information on this impact, see the
Coordination with Medicare section in the Summary Plan Description for your P&G active health
coverage.
If you continue to receive P&G active health coverage during the extension of benefits period, you may
be entitled to continue your health and dental coverage under COBRA when the extension of benefits
period ends. If you are entitled to COBRA continuation coverage, you will receive a notice of your
right to elect COBRA.
Retiree Medical and Dental Benefits: If you were eligible for P&G retiree healthcare coverage on your Employment Separation Date, you
will be eligible to enroll in P&G’s retiree medical and dental insurance coverage. You are eligible for
P&G retiree healthcare coverage if you satisfy the regular retiree eligibility rules (i.e., you are a
Regular Retiree) as of your Employment Separation Date. Under the terms of this Agreement, you also
are eligible for P&G retiree healthcare coverage as a Special Retiree by satisfying the Rule of 70 as of
your Employment Separation Date. You satisfy the Rule of 70 when your full years of age plus your
full years of service equal 70. If you are eligible for P&G’s retiree healthcare coverage as either a
Regular Retiree or a Special Retiree as of your Employment Separation Date, you should contact P&G
Benefits Services before your extension of coverage ends to request retiree healthcare enrollment
information. For details regarding the terms and conditions of your retiree health coverage, please refer
to and review the summary plan descriptions, available at the P&G Benefits website.
Important Note: If you become employed by a direct competitor of P&G (as determined by P&G’s
Chief Human Resources Officer) in an officer and/or director capacity, you will not be eligible for
coverage under P&G’s retiree healthcare coverage as long as you remain employed by such competitor.
If you have questions, please contact P&G Benefits Services at 1-844-786-6588.
Special rules apply to Gillette Heritage Employees with regard to retiree medical eligibility and the retiree medical cost sharing under the retiree medical plan.
If you are a Gillette Heritage Employee, you will receive a separate handout on your retiree medical eligibility.
1
1

-- 36 of 48 --

Outplacement Services: 	P&G’s preferred third-party provider will provide services to assist you in managing your transition to
a new future, based on your interest. Services include pre-decision counseling, career transition
programs, and job development opportunities. P&G’s preferred third-party provider will also assist you
in preparing for your job search, including résumé preparation, cover letters, other written materials
and interview and networking training.
After accepting this Agreement, and after obtaining your manager’s approval, you may begin utilizing
outplacement services on a limited basis prior to your Employment Separation Date, consistent with the
needs of the business and your responsibilities to complete and/or transition your work. Note that you
must begin utilizing outplacement services within 45 days of your Employment Separation Date to be
eligible for this benefit.
No Consideration Without Executing
this Agreement:
You affirm that you understand and agree that you would not receive the separation payment and/or
benefits specified in this Agreement without executing this Agreement and fulfilling the promises
contained in it. Except as provided in this Agreement or under the terms and conditions of an
applicable benefit plan or policy sponsored by P&G, you shall not be due any payments or benefits
from P&G in connection with your separation from employment.
Continued Employment Through
Your Employment Separation Date:
You agree to perform your work and responsibilities as an employee in a satisfactory manner up to and
including your Employment Separation Date, including compliance with all provisions of this
“Separation Agreement and Release.” If P&G determines that you have engaged in misconduct during
your employment, you understand and agree that P&G may terminate your employment immediately
and will not provide, nor will it be obligated to provide, you with the Separation payment, medical
benefits, outplacement, retraining and other benefits described above. If you have already received any
such pay or benefits, you agree to repay them to P&G upon demand.
No Admission of Wrongdoing: 	You affirm that you understand and agree that neither this Agreement nor the furnishing of the
consideration for this Agreement, including the Separation Payment, shall be deemed or construed at
any time for any purpose as an admission by P&G of wrongdoing or evidence of any liability or
unlawful conduct of any kind.

-- 37 of 48 --

Release of Claims – Including Age
Discrimination and Employment
Claims:
[IF THE EMPLOYEE IS A RESIDENT OF: CALIFORNIA, MASSACHUSETTS, MINNESOTA,
NEW JERSEY, OR WEST VIRGINIA, REPLACE THE BELOW LANGUAGE WITH THE STATE-
SPECIFIC LANGUAGE THAT CAN BE FOUND HERE: State Specific Release Language.docx]
You hereby release P&G from any and all claims or rights you may have against P&G. The term
“P&G” includes, «Company», The Procter & Gamble Company and any of its and their present, former
and future owners, parents, affiliates and subsidiaries, and its and their directors, officers, shareholders,
employees, agents, benefit plans, trustees, fiduciaries, servants, representatives, predecessors,
successors and assigns. This release applies to claims about which you now know or may later
discover, and includes but is not limited to: (1) claims arising under the Age Discrimination in
Employment Act ("ADEA"), 29 U.S.C. § 621, et seq.; (2) claims arising under any other federal, state
or local law, regulation or ordinance or other order that regulates the employment relationship and/or
employee benefits; and (3) claims arising out of or relating in any way to your employment with P&G
or the conclusion of that employment. This release does not apply to claims that may arise after the
date you sign this letter or that may not be released under applicable law.
You are not waiving any rights you may have to: (a) your own vested accrued employee benefits under
the P&G health, welfare, or retirement benefit plans as of your Employment Separation Date; (b)
benefits and/or the right to seek benefits under applicable workers’ compensation and/or unemployment
compensation statutes; (c) pursue claims which by law cannot be waived by signing this Agreement;
(d) enforce this Agreement; and/or (e) challenge the validity of this Agreement.
Governmental Agencies: Nothing in this Separation Letter & Release prohibits, prevents, or otherwise
limits you from filing a charge or complaint with or participating, testifying, or assisting in any
investigation, hearing, or other proceeding before any federal, state, or local government agency (e.g.,
EEOC, NLRB, SEC, OSHA, etc.) or in any legislative or judicial proceeding nor does anything in this
Separation Letter & Release preclude, prohibit, or otherwise limit, in any way, your rights and abilities
to contact, communicate with, or report unlawful conduct, or provide documents, to federal, state, or
local officials for investigation or participate in any whistleblower program administered by any such
agencies. In addition, nothing in this Separation Letter & Release, including, but not limited to, the
release of claims nor the confidential business information, and return of company property clauses,
prohibit you from: (1) reporting possible violations of federal or other law or regulations, including any
possible securities laws violations, to any governmental agency or entity, including but not limited to
the U.S. Department of Justice, the U.S. Securities and Exchange Commission, the

-- 38 of 48 --

Commodity Futures Trading Commission, the U.S. Congress, or any agency Inspector General; (2)
making any other disclosures that are protected under the whistleblower provisions of federal or other
law or regulations; or (3) filing a charge or complaint or otherwise fully participating in any
governmental whistleblower programs, including but not limited to any such programs managed or
administered by the U.S. Securities and Exchange Commission, the Commodity Futures Trading
Commission or the Occupational Safety and Health Administration. You are not required to notify or
obtain permission from P&G when filing a governmental whistleblower charge or complaint or engaging
or participating in protected whistleblower activity. Moreover, nothing in this Separation Letter &
Release prohibits or prevents you from receiving individual monetary awards or other individual relief
by virtue of participating in such governmental whistleblower programs.

-- 39 of 48 --

Confidential, Proprietary, Trade
Secret Information: Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you agree that you will not use or share any
confidential, proprietary or trade secret information about any aspect of P&G’s business with any non-
P&G employee or business entity at any time in the future. You further agree that you will not obtain,
transfer or have in your possession any confidential, proprietary or trade secret information on or after
your Employment Separation Date, even information you may have created yourself or to which you
may have contributed as a P&G employee. Confidential, proprietary or trade secret information
includes, but is not limited to, marketing and advertising plans, pricing information, upstream plans,
specific areas of research and development, project work, product formulation, processing methods,
assignments of individual employees, testing and evaluation procedures, cost figures, construction
plans, and special techniques or methods of any kind.
Notwithstanding the requirements of confidentiality contained in this section, the federal Defend Trade
Secrets Act of 2016 immunizes you against criminal and civil liability under federal or state trade secret
laws for your disclosure of trade secrets that is made i) in confidence to a federal, state, or local
government official, either directly or indirectly, or to an attorney solely for the purpose of reporting or
investigating a suspected violation of law; ii) in a complaint or other document filed in a lawsuit or
other proceeding, if such filing is made under seal; or iii) to your attorney for use in a lawsuit alleging
retaliation for reporting a suspected violation of law, provided that any document containing the trade
secret is filed under seal and you do not otherwise disclose the trade secret, except pursuant to court
order.
For the purposes of this section, it shall be conclusively presumed that you have knowledge or
information to which you were directly exposed through the actual receipt of memos or documents
containing such information or through actual attendance at meetings at which such information was
discussed or disclosed. The provisions of this section are not in lieu of, but are in addition to, your
continuing obligation to not use or disclose P&G’s trade secrets and confidential information known to
you until any particular trade secret or confidential information becomes generally known (through no
fault of yours). Information regarding products in development, in test market or being marketed or
promoted in a discrete geographic region, which information P&G is considering for a broader use,
shall not be deemed generally known until such broader use is actually commercially implemented.
Also, “generally known” means known throughout the domestic United States industry or, if you have
job responsibilities outside of the United States, the appropriate foreign country or countries’ industry.
If any restriction in this section is found by any court of competent jurisdiction or arbitrator to be
unenforceable because it extends for too long a period of time or over too great a range of activities or
in too broad

-- 40 of 48 --

a geographic area, it will be modified and interpreted to extend only over the maximum period of time,
range of activities or geographic area so that it may be enforceable.
If you are a participant in the Procter & Gamble 2009 Stock and Incentive Compensation Plan you are
also bound by the terms of Article F – Restrictions & Covenants of those plans, which are incorporated
herein by reference.
If you are a participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the
Procter & Gamble 2014 Stock and Incentive Compensation Plan, you are also bound by the terms of
Article 6 – Restrictions and Covenants of those plans which are incorporated herein by reference.
Non-Solicitation: 	Delete this section if employee is B5 or below
You acknowledge, as a participant in the Procter & Gamble 2019 Stock and Incentive Compensation
Plan, the Procter & Gamble 2014 Stock & Incentive Compensation Plan, the Procter & Gamble 2009
Stock and Incentive Compensation Plan, the Procter & Gamble 2001 Stock and Incentive Plan, the
Procter & Gamble 1992 Stock Plan, and/or the Gillette Company 2004 Long-Term Incentive Plan that
you are bound to comply with the Plans’ non-solicitation obligations. Specifically, you agree that you
will not, for 5 years following your Employment Separation Date, attempt to directly or indirectly
induce any employee of P&G or its affiliates or subsidiaries to be employed or perform services
elsewhere or attempt directly or indirectly to solicit the trade or business of any current or prospective
customer, supplier or partner of P&G or its affiliates or subsidiaries.
Acknowledgements and
Affirmations:
Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you affirm that you have not filed, caused to be filed,
or presently are a party to any claim against P&G.
You affirm that you have been paid and/or have received all compensation, wages, bonuses,
commissions, and/or benefits which are due and payable as of the date you sign this Agreement. To the
extent that you are required to report hours worked, you affirm that you have reported all hours worked
as of the date you sign this Agreement.
You affirm that you have been granted any leave to which you were entitled under the Family and
Medical Leave Act or related state or local leave or disability accommodation laws.
You further affirm that you have no known workplace injuries or occupational diseases that have not
been reported.

-- 41 of 48 --

Assignment of Intellectual Property: You will promptly and fully disclose, transfer and assign to P&G all inventions and any other intellectual
property (collectively “Intellectual Property”) made or conceived by you during your employment with
P&G. You agree to fully cooperate in executing any papers required for establishing or protecting the
Intellectual Property and for establishing P&G’s ownership, even if such cooperation is necessary after
your Employment Separation Date.
Return of P&G Property: 	You agree that by your Employment Separation Date, you will return to P&G in good condition all of
its equipment, materials and information that were in your possession, custody or control (including, but
not limited to, work product, notes, files, memoranda, instructional or personnel manuals, computers,
phones, iPads, tablets files, documents, credit cards, keys and identification badges). You further agree
that you will provide your manager with all passwords to P&G electronic communication and data
systems before your Employment Separation Date.
You understand and agree that technical, product, business, financial, personnel, and other physical or
personal property that you received, prepared, or helped to prepare in connection with your employment
with P&G, is P&G property and must be returned to P&G prior to your Employment Separation Date.
You further understand and agree that if P&G later discovers that you retained and/or forwarded to
yourself P&G property, you will have violated the terms of this Separation Letter & Release, P&G will
not be obligated to provide the benefits described in this Letter, and you will be required to return any
benefits received under this Separation Letter & Release.
Ethics Compliance: 	Subject to the “Governmental Agencies” portion of the “Release of Claims – Including Age
Discrimination and Employment Claims” above, you agree that you provided P&G all information
known to you regarding any violations of the Procter & Gamble Worldwide Business Conduct Manual
and/or any other violations of P&G policy or the law.
Severability: 	If any court of competent jurisdiction or arbitrator should later find that any portion of this Agreement is
invalid, that invalidity will not affect the enforceability of any other portion of this Agreement.
Employment References: 	Pursuant to P&G’s standard policies, in connection with any and all potential employers seeking
references directly from P&G, you agree to refer all such reference inquiries to P&G’s employment
verification vendor. Information can be found on the GetHelp Portal by searching “Employment and
Income Verification”.

-- 42 of 48 --

No Reliance: 	This Agreement sets forth the entire agreement between you and P&G and fully supersedes any prior
agreements or understanding between the parties except that if you are a participant in the Procter &
Gamble 2009 Stock and Incentive Compensation Plan, the terms of Article F – Restrictions & Covenants
of those plans remain in full force and effect and are incorporated herein by reference and if you are a
participant in the Procter & Gamble 2019 Stock and Incentive Compensation Plan or the Procter &
Gamble 2014 Stock and Incentive Compensation Plan, the terms of Article 6 – Restrictions & Covenants
of those plans remain in full force and are in effect and are incorporated herein by reference. In deciding
to accept this Agreement, you agree that you have not relied upon any statements or promises by P&G,
its managers, agents or employees, other than those set forth in this Agreement. No other promises or
agreements concerning the matters described in this Agreement shall be binding unless in a subsequent
document signed by these parties.
Your Attorney: 	You acknowledge that you have been and hereby are advised to consult with legal counsel before
accepting this Agreement and have either done so or have voluntarily declined to do so.
Timing for Acceptance or
Revocation:
You have forty-five (45) calendar days in which to consider this Agreement in which you waive
important rights, including those under the Age Discrimination in Employment Act of 1967. If you
choose to sign this Agreement, please do so by indicating your acceptance of this Agreement with your
electronic signature in P&G’s electronic system. We advise you to consult with an attorney of your
choosing prior to signing this Agreement. Further, you may within seven (7) calendar days following
the date you accept this Agreement, cancel and terminate the Agreement by giving written notice of
your intention to revoke the Agreement to your immediate manager, and by returning to P&G any
remuneration or benefits that have been advanced to you in anticipation of your not revoking your
Agreement and to which you are not entitled. If notice of your revocation is mailed, it must be
postmarked within seven (7) calendar days after you sign this Agreement.
You agree that any modifications, material or otherwise, made to this Agreement, do not restart or affect
in any manner the original up to forty-five (45) calendar day consideration period.
Applicable Law: 	Ohio law will apply in connection with any dispute or proceeding concerning this Agreement without
regard to Ohio’s conflict of laws provisions.
The benefits described in this Agreement and pursuant to the Summary Plan Description for the Procter & Gamble Basic Separation Program for
U.S. Employees (to be obtained from your HR Business Partner), are the special benefits you will receive by signing this Agreement. To the
extent this Agreement describes benefits under other benefit plans and policies sponsored by P&G, these special benefits are also described in
the summary plan descriptions for those plans. As such, nothing in this Agreement amends or changes the terms of any P&G-sponsored
employee benefit plan or policy.
After your Employment Separation Date, you will no longer be an active P&G employee, which may affect your coverage under those plans and
policies. For example, plans may require that you enroll in

-- 43 of 48 --

Medicare to be eligible for coverage. For more information on how not being an active P&G employee may affect your coverage, please refer to
and review the summary plan descriptions for each plan.
To accept this separation package according to the terms of the above Agreement, go back to the e-mail and electronic link you received and
click on the “Accept” button. By clicking “Accept,” you acknowledge that you have read the entire Agreement, that you understand it, and that
you voluntarily accept its terms. You further agree that you understand that it is a legally binding agreement, that you have been advised to
consult with an attorney, that you have been given 45 days to consider the Agreement, and that you can revoke your acceptance within seven
days of accepting the Agreement by providing written notification to your immediate manager. If you do not wish to accept the terms of this
Agreement, click on the “Decline” button.

-- 44 of 48 --

EXHIBIT 31.1
Rule 13a-14(a)/15d-14(a) Certifications
I, Jon R. Moeller, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
April 24, 2025
Date

-- 45 of 48 --

EXHIBIT 31.2
Rule 13a-14(a)/15d-14(a) Certifications
I, Andre Schulten, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
April 24, 2025
Date

-- 46 of 48 --

EXHIBIT 32.1
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2025 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
April 24, 2025
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 47 of 48 --

EXHIBIT 32.2
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2025 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
April 24, 2025
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 48 of 48 --